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  As a well spent day bring happy sleep, 
  So life, well used, bring happy death. 
  Time abides long enough, 
  For those who make use of it. 
 
  - Leonardo da Vinci - 
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ABSTRACT 
 
Idiopathic pulmonary fibrosis is the most common of the idiopathic interstitial pneumonias, and is 
distinguished from other interstitial pneumonias by the histological pattern, clinical manifestation, 
and poor outcome with usual survival of less than three years. There is no curative treatment yet 
available. The pathogenesis and etiology of idiopathic pulmonary fibrosis are unknown. The reports 
of multiple affected family members in the same family observed worldwide support the influence 
of genetic factors in the etiology.  
 
In this study we evaluated the first nationwide prevalence of idiopathic pulmonary fibrosis using the 
recent diagnostic criteria. In Finland the prevalence of idiopathic pulmonary fibrosis was 16-
18/100 000 inhabitants. The prevalence revealed variation in geographical distribution. In eastern 
and southern Savo, the prevalence was 45/100 000 inhabitants. We identified multiplex families 
with idiopathic pulmonary fibrosis, and calculated that the prevalence of familial idiopathic 
pulmonary fibrosis is 5.9/1 million population in Finland, explaining 3.3-3.7% of all idiopathic 
pulmonary fibrosis. The origins of the patients with familial idiopathic pulmonary fibrosis tended to 
cluster within the Savo and the nearby Carelia regions. Although no obvious genealogical loops 
between the families were observed, the clustering can be explained by a founder effect, i.e. the 
affected family members most likely share a common disease causing allele introduced by a 
common ancestor. 
 
Parallel to the mapping of novel susceptibility genes for idiopathic pulmonary fibrosis, we tried to 
identify polymorphisms within candidate genes which could functionally play a part in the 
pathogenesis of the disease. Increased activity of extracellular superoxide dismutase in the 
extracellular matrix protects against lung injury caused by free radicals, and a synonymous 
Arg213Gly polymorphism in the extracellular superoxide dismutase gene is reported to result in 
higher serum levels. To study the possibility of an association of the Arg213Gly polymorphism 
with idiopathic pulmonary fibrosis we screened 63 patients and 61 population based controls.  One 
of the patients and three controls carried the Gly213 allele, thus no association was detected. 
Association with the Pro1827Arg polymorphism of the Complement receptor 1 gene was studied 
among 96 patients and 164 controls. None of the 520 chromosomes studied carried the Arg1827 
allele. 
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We performed a genome-wide scan with six multiplex families. Three regions on chromosomes 3, 
4, and 13 obtained NPL scores of 1.7, 1.7, and 1.6, respectively, and on chromosomes 9 and 12 
possible shared haplotypes were seen. These five loci were selected for fine mapping in an extended 
data set with the original six pedigrees, two additional multiplex families, four singletons, and 12 
trios originating from the enrichment area. After hierarchial fine mapping with 63 markers on 
chromosomes 3q13 and 13q31 the NPL scores increased to 2.1 and 2.4, respectively, but no shared 
haplotype associated with the disease was detected, and the shared haplotypes on chromosomes 9 
and 12 broke down. On chromosome 4q31.1 the NPL score increased to 2.1, and a 110 kb shared 
haplotype was carried by one third of the affected families (8/24), while none of the unaffected 
family members carried it. The carriership of the susceptibility haplotype was 34% among all the 
genotyped uniplex and multiplex families (12/35), and 7.7% (11/143) among 143 controls (27 
family based, 23 regional, and 93 Finnish unrelated controls). The susceptibility haplotype obtained 
an odds ratio of 6.3 (p=0.0001, 95%CI=2.3–15.9). The critical region harbors two novel candidate 
genes, ELMOD2, and LOC152586. An in vitro translation assay of LOC152586, however, failed to 
yield a stable polypeptide. mRNA expression of ELMOD2 was decreased in lung biopsies derived 
from patients suffering from idiopathic pulmonary fibrosis (N=6) compared to healthy controls 
(N=7). Based on its expression and functional properties, potentially being involved in apoptosis, 
phagocytosis, cell engulfment, and cell migration, ELMOD2 is a prime positional candidate 
susceptibility gene for familial IPF. 
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INTRODUCTION 
 
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Patients suffer from 
cough and dyspnoe for two years on average before diagnosis (King et al. 2001). According to the 
recent international diagnostic criteria, IPF refers to the histological pattern of usual interstitial 
pneumonia (UIP) (ATS 2000). IPF differs from other idiopathic interstitial pneumonias (IIP) in 
terms of disease pattern, response to immunosuppressive therapy, and lethal outcome. The average 
survival after diagnosis is less than three years (Nicholson et al. 2000, Collard et al. 2003). No 
curative treatment is yet available.  
 
The etiology and pathogenesis of IPF remain unknown. IPF is a multifactorial disease in which 
genetic factors also interact. The most convincing evidence of the importance of genetic factors is 
based on reports on familial cases worldwide (Peabody et al.1950, Bonnani et al. 1965, Javaheri et 
al. 1980, Uchiyama et al. 1997, Marshall et al. 2000, Thomas et al. 2002, Lee et al. 2005, Steele et 
al. 2005). Familial and sporadic IPF do not seem to differ in either their clinical characteristics or 
outcome (Marshall et al. 2000, Lee et al. 2005). Thus results from studies on familial IPF can reveal 
genes and molecular signalling pathways also important in sporadic IPF. Attempts to study the 
genetics of IPF have been mostly based on association studies with candidate genes (Whyte et al. 
2000, Hutyrova et al. 2002, Latsi et al. 2003, Zorzetto et al. 2003, Lawson et al. 2004), but the 
reported associations have remained unconfirmed. IPF affects patients at older ages, which offers a 
challenge to gather informative multiplex families to perform linkage studies. Defining a precise 
phenotype is crucial; several interstitial pneumonias have been misdiagnosed as IPF. The recent 
diagnostic criteria and better imaging technologies such as high resolution computed tomography 
(HRCT) are likely to reduce the confusion. Based on the difficulties in phenotyping and in 
collecting multiplex families genome wide scans of IPF have not previously been published. 
 
Trying to detect linkage in a complex disease using genetically isolated populations has been shown 
to be in some cases advantageous (Lander and Schork 1994, Risch 2000). The Finns have lived in 
isolation for centuries, and the population remained small until it expanded only during the last 
century. The genetic diversity is limited, shaped by founder effects, genetic drift, and isolation (de 
la Chapelle and Wright 1998, Peltonen et al. 2000, Kere 2001). Founder populations, such as the 
Finns, exhibit linkage disequilibrium and haplotype sharing over long genetic distances, and 
patients have most probably inherited the same disease-causing allele from a common ancestor. 
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Using population isolates has resulted in successful identification of disease-related genes and 
molecular genetic mechanisms in complex diseases such as asthma and hyperlipidemia (Laitinen et 
al 2004, Pajukanta et al. 2004). With the advantages of population isolates and precise phenotyping, 
mapping genes responsible for IPF may be successful. 
 
This study attempted to identify genetic factors that may be relevant in the pathogenesis of IPF. We 
started with an epidemiological study by evaluating the prevalence of IPF in Finland, which was the 
first nationwide prevalence study using the novel international classification, and we identified 
multiplex families with at least two family members with IPF. Polymorphisms Pro1827Arg in the 
gene for Complement receptor 1 and Arg213Gly for the ECSOD gene had been verified and are 
likely to result in functional changes (Xiang et al. 1999, Folz and Crapo 1996). Pro1827Arg had 
already been suggested to be associated with IPF (Zorzetto et al. 2003). We aimed to study the 
association of these polymorphisms with IPF among Finnish patients. With multiplex families we 
performed a genome-wide scan to detect possible linkage to IPF. With an additional study 
population, we went further to perform haplotype association studies aimed at limiting a critical 
region in order to identify candidate genes for IPF using the methods of positional cloning. 
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REVIEW OF THE LITERATURE 
 
1. IPF 
 
1.1 From history to novel classification 
 
The earliest description of IPF is considered to be a publication by Hamman and Rich in 1944. 
Three patients, who were treated at the John Hopkins Hospital from the years 1931 to 1933, 
suffered from extreme dyspnoea and cyanosis in a way that was new to the physicians. The patients 
died within three weeks to three months after entering the hospital. At autopsy the lungs showed 
widespread connective tissue hyperplasia throughout the interstitial structures, and the alveolar 
walls were replaced by scar tissue. In 1967, Scadding and Hinson reported on sixteen patients with 
diffuse fibrosing alveolitis. The progressive inflammatory and fibrous interstitial diseases were 
verified by surgical lung biopsy performed by thoracotomy. Because it became obvious that 
idiopathic intersitial diseases included various clinical conditions, they have been classified into 
distinguishable entities according to their histological appearance since 1969. The first pathological 
classification by Liebow and Carrington (1969) included five subtypes: usual interstitial pneumonia 
(UIP), desquamative interstitial pneumonia (DIP), bronchiolitis obliterans with interstitial 
pneumonia (BIP), lymphoid interstitial pneumonia (LIP), and giant cell interstitial pneumonia 
(GIP). In the 1980`s, large studies described the clinical features and outcome of IPF, or as it was 
previously called, cryptogenic fibrosing alveolitis (Turner-Warwick et al. 1980, Tukiainen et al. 
1983). In 1998, Katzenstein and Myers offered a renewed classification based upon the 
identification and definition of new histopathological entities. They divided the IIPs into four 
subtypes: UIP, DIP, acute interstitial pneumonia (AIP), and non-specific interstitial pneumonia 
(NSIP). Because the overlapping of the clinical entities – their symptoms, radiological and 
histological findings, and the diseases courses – caused some confusion in the diagnostic criteria 
and terminology, there was a need for a novel international standard. In 2002 an international 
consensus statement defining the clinical, radiologic, and pathologic approach to the classification 
of IIPs was produced as a collaborative effort of the American Thoracic Society (ATS), European 
Respiratory Society (ERS), and American College of Chest Physicians (ACCP) (ATS 2002). The 
novel classification, valid today, divides the IIPs into IPF, and IIPs other than IPF comprising DIP, 
respiratory bronchiolitis with interstitial lung disease (RBILD), AIP, cryptogenic organizing 
pneumonia (COP), NSIP, and LIP. IPF represents approximately 60% of all IIPs (Bjoraker 1998, 
Thomeer 2001, Gross and Hunninghake 2001). 
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1.2 Epidemiology 
 
There are limited data on the epidemiology of IPF. One of the oldest prevalence estimates 
frequently referred to in the literature, from 3 to 5/100 000, is based on the Lung Program published 
in 1972 by The National Heart and Lung Institute in the United States (DHEW 1972). In the 
Moravian and Silesian populations of the Czech Republic, where the proportion of biopsy-verified 
cases was 38%, the prevalence tended to increase from 7 to 12/100 000 during the years 1981 to 
1990 (Kolek 1994). A large epidemiological study in New Mexico reported the prevalence of IPF 
for males as 20 and for females as 13/100 000, when the diagnosis was confirmed by clinical or 
autopsy data (Coultas et al. 1994). Some of the studies focus mainly on population cohorts which 
have been exposed to fibrogenic dusts. According to those studies the prevalence estimates for IPF 
have ranged from 3 to 6/100 000 (Iwai et al. 1994, Hubbard et al. 1996, Scott et al. 1990). All of 
these studies were conducted before the novel IIP classification, and it is likely that these figures 
include a mixture of several subtypes of IIPs counted as IPF. The incidence estimates are not 
precise either, suggesting incidences of 11 for males and 7/100 000 per year for females (Coultas et 
al.1994), and increases with advancing age (Scott et al. 1990, Mannino et al. 1996, Coultas et al. 
1994). 
 
IPF has been reported worldwide (Kolek 1994, Coultas et al. 1994, ATS 2000, Zorzetto et al. 2003, 
Miyake et al. 2005). Some predominance in males is observed (Coultas et al. 1994). The mortality 
for IPF is estimated to be 1-3.3/100 000 in Japan (Iwai et al. 1994). Some evidence that age-
adjusted mortality rates are higher among whites than blacks has been shown (Mannino et al. 1996). 
This might just reflect inadequate reporting rather than differences in the disease course. Variation 
in the age-adjusted mortality from IPF is also observed among different geographical areas in the 
United States; lowest in the midwest and northeast and highest in the west and southeast, and in the 
United Kingdom; highest in industrialized central areas of England and Wales (Mannino et al.1996, 
Johnston et al. 1990). This variation is, however, thought to reflect merely the poor exclusion of 
occupational and environmental fibrogenic exposures, and might be related to inadequate diagnostic 
criteria  (ATS 2000, Fellrath and duBois 2003).  
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1.3 Etiology 
 
Several environmental factors have been studied as triggers of the disease. Viral infections have 
been associated with the pathogenesis of IPF. Epstain-Barr virus (EBV) has been studied using 
various approaches. An association between IPF and serological evidence of active EBV infection 
is observed (Vergnon et al. 1984). Egan and collagues (1995) reported EBV capsid antigen in 
epithelial cells of IPF patients by immunofluorescent staining. A high incidence of co-existent or 
preceding influenza, cytomegalovirus, and hepatitis C infections have been reported among IPF 
patients, and thereby these have been proposed as etiological agents (ATS 2000). 
 
Numerous environmental exposures have been offered as etiological candidates. Metal and wood 
dust exposure, especial dust containing steel, brass, lead, and pine wood, have been associated with 
IPF (Iwai et al. 1994, Scott et al.1990, Hubbard et al. 1996, Baumgartner et al. 2001). In these 
studies the diagnosis of IPF was not verified with HRCT and/or biopsy specification, which 
diminishes the reliance of the observed associations. 
 
Cigarette smoking has been identified as a potential risk factor with an odds ratio (OR) of 2.9 (Ryu 
et al. 2001). A surprising observation has been reported that current smokers with IPF survive 
longer than non-smokers (King et al. 2001). It is possible that ingredients of tobacco smoke may 
affect fibroblast function. It is also possible that smokers express other respiratory tract-related 
illnesses, such as chronic bronchitis and emphysema, causing symptoms such as cough and 
dyspnoe, and their IPF is diagnosed earlier – paradoxically leading to better survival than seen 
among non-smokers. 
 
The use of antidepressants and chronic aspiration have also been suggested as etiological factors of 
IPF (Hubbard et al. 1998, Tobin et al. 1998).  
 
Autoimmune activity may be increased in IPF. Patients with IPF often express systemic symptoms 
such as fever and arthralgia. Some are positive for rheumatoid factor (19%) and/or antinuclear 
factor (26%), and antibodies against antisynthetases (Holgate et al. 1983, duBois and Wells 2001, 
Imbert-Masseau et al. 2003) as markers of autoimmune activity. A recent study showed that an 
interaction between an endogenous antigen, expressed by type II epithelial cells, and circulating 
auto-antibodies results in increased TGF-β and tenascin production. That experiment suggests that 
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the biological activity of autoantibodies may play a role in the pathogenesis of IPF (Wallace and 
Howie 2001). 
 
1.4 Pathological findings 
 
For a long time it was supposed that IPF is an inflammatory disease with chronic alveolitis 
preceding fibrotic response (Keogh and Crystal 1982). It has become obvious from multiple 
sources, however, that inflammation is not the trigger for fibrogenesis of IPF type (Selman et al. 
2001, Pardo and Selman 2002). Inflammatory cells and intra-alveolar macrophage accumulation do 
not belong to the major histological features of IPF. Alveolitis, if it is observed, is mild and seen in 
late and early diseases, indicating that inflammation does not have to precede fibrosis (Katzenstein 
and Myers 1998). Adamson and his collagues (1998) showed that severe injury and retarded repair 
of alveolar epithelium disturbs normal epithelial-fibroblast interactions and is sufficient to promote 
fibrosis without preceding inflammation. Immunosuppressive and anti-inflammatory treatments 
used for years in the treatment of IPF do not improve disease outcome (ATS 2000). 
 
The most recent hypothesis is based on an abnormal wound healing process. The proper fibrotic 
cascade is not known, but various steps are speculated. A schematic illustration of hypothesized 
pathogenesis is shown in Figure 1. Many environmental, physical, and chemical factors generate 
reactive oxidative molecules that cause nonspecific damage to cells and the extracellular matrix 
(ECM) when produced in excess (Kinnula and Crapo 2003). Multiple injuries damage and activate 
alveolar epithelial cells (AEC) (Pardo and Selman 2002). AECs synthesize molecules, such as 
tissue factors and plasminogen activator inhibitors (PAI-1 and PAI-2), that are profibrotic and also 
procoagulant (Imokawa et al. 1999). AECs express multiple cytokines and growth factors. AECs 
seem to be the main sites of synthesis of platelet-derived growth factor, transforming growth factor 
(TGF-β), tumor necrosis factor alfa (TNF-α), connective tissue growth factor, and endotelin-1 (ET-
1), which induce migration and proliferation of fibroblasts (Antoniades et al. 1990, Giaid et al. 
1993, Kapanci et al. 1995, Pan et al. 2001, Pardo and Selman 2002, Chambers et al. 2003, Shi-wen 
et al. 2004).   
 
Intra-alveolar activation of the coagulation cascade has been documented in pulmonary fibrosis. 
Plasmin can degrade a number of ECM molecules and activate procollagens (Kotani et al. 1995; 
Fujimoto et al. 2003). Direct thrombin inhibition decreases lung collagen accumulation in 
bleomycin-induced pulmonary fibrosis in mice (Howell et al. 2001). 
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Myofibroblasts within the early fibrotic lesions, as well as intra-alveolar and interstitial activated 
fibroblasts and myofibroblasts, and type 2 pneumocytes produce ECM proteins (Selman et al. 1986, 
Pääkkö et al. 2000, Ramos et al. 2001). ECM is composed of fibronectin, elastic fibers, 
proteoglycans such as tenascin, and especially composed of abundant fibrillar collagens. The 
activated fibroblasts, myofibroblasts and ECM form fibroblastic foci, pathognomonic of IPF. An 
imbalance between matrix metalloproteinases (MMPs) that break down matrix proteins and their 
inhibitors, tissue inhibitors of matrix metalloproteinases (TIMPs), lead to the progressive deposition 
of ECM (Selman et al. 2000, Ruiz et al. 2003). MMPs may also cause the release of fibrosis-
promoting cytokines and growth factors and lead to the initiation and progression of pulmonary 
fibrosis (Winkler and Fowlkes 2002).  Interstitial neovascularization may enhance fibrogenesis, but 
the role of angiogenic molecules is still unclear (Keane et al. 1997). Factors that have angiogenic 
activity (interleukin-8 [IL-8], epithelial neutrophil-activating peptide-78) were found at higher 
levels in tissue specimens of IPF patients (Keane 1997, Keane 2001), and high serum levels of 
vascular endothelial growth factor (VEGF), IL-8, and ET-1 appear to have a role in the progression 
of IIP (Simler et al. 2004). 
 
Myofibroblasts produce 1) angiotensinogens such as angiotensin II that provokes AEC apoptosis, 
and 2) gelatinises A and B, that may increase basement membrane disruption and allow fibroblast 
migration that in turn might hamper the repair of AECs (Ramos et al. 2001, Ruiz et al. 2003).  
These mechanisms further provoke unsuccessful re-epithelization. 
 
There is evidence that, besides alveolar epithelium, bronchiolo-alveolar junctions also represent a 
relevant and specific target of injury in IPF (Chilosi et al. 2002). Epithelial cells of IPF patients 
expressing ∆N-p63, a member of the p53 tumor suppressor gene family, were observed at sites of 
abnormal proliferation at the bronchiolo-alveolar junctions, characterized by epithelial hyperplasia, 
squamous metaplasia, and abnormal p53 nuclear accumulations – features that were not observed in 
normal lung, or in COP, NSIP, DIP, or AIP lung (Chilosi et al. 2002). The products of the p53 gene 
family may also reflect the malignant transformation observed in IPF (Turner-Warwick et al. 1980, 
Chilosi et al. 2002,). 
 
Based on present evidence, it is proposed that the earliest morphologic change associated with 
progressive fibrosis is the presence of fibroblastic foci (Kuhn and McDonald 1991, Kazenstein and 
Myers 1998, King et al. 2001). Fibroblasts within these foci keep modifying their phenotypes, 
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parallel to that seen in skin wounds, from a migratory through a proliferative phase to a profibrotic 
phenotype, producing ECM components (Selman et al. 2001). Whether fibroblasts from patients 
with IPF are genetically susceptible to abnormal response after lung injury is not clear. 
 
 
 
 
Figure 1. A schematic illustration of possible steps from injury to usual interstitial pneumonia (UIP) 
(modified from Selman et al. 2001). Multiple injuries damage alveolar epithelial cells (AECs). Activated AECs 
secrete antifibrinolytic tissue factors plasminogen activator inhibitors (PAI) -1 and -2, which provoke wound 
clot formation. Activated AECs also secrete several growth factors and cytokines that enhance fibroblast 
migration and proliferation, and differentiation into myofibroblasts. Proliferated fibroblasts and myofibroblasts 
secrete extracellular matrix (ECM) proteins, mainly collagens, and tissue inhibitors of metalloproteinases 
(TIMPs), which in turn favors in imbalance fibrinogenetic deposition of ECM over fibrinolysis. Angiogenic 
factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF) enhance 
neovascularization. Myofibroblasts and AECs secrete gelatinases that damage basement membrane, and 
angiotensinogens that induce AEC death. Both of these result in impaired re-epithelization.             
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1.5 Diagnosis of IPF 
 
Patients with IPF typically suffer from shortness of breath and cough for more than six months 
before diagnosis. General symptoms, such as fever, arthralgia and myalgia, may also occur. Digital 
clubbing is seen in around 50% of the patients. Auscultation of the lungs reveals fine bibasilar 
inspiratory cracles (Velcro rales). The average age at the time of diagnosis is 60-66 years (Turner-
Warwick et al. 1980, Johnston et al. 1997, Lee et al. 2005). It is important to exclude other causes 
of interstitial pulmonary diseases. IPF is also seen as pulmonary involvement in various systemic 
diseases, such as rheumatoid arthritis (RA) and systemic sclerosis (Wells et al. 1993). IPF type 
fibrosis is considered to be the most common pulmonary manifestation of RA, present in 
approximately 20% of outpatients (Dawson et al. 2001), although a pathological approach suggests 
that cases previously classified as IPF are likely to show a pattern of NSIP rather than UIP, 
particularly in relation to systemic sclerosis (Nicholson et al. 2002). The median survival from 
diagnosis is 2.5-4.5 years (Schwarz et al. 1994, Nicholson et al. 2000, King et al. 2001, Collard et 
al. 2003). 
 
There are no specific laboratory findings for IPF. Bronchoalveolar lavage (BAL) fluid cell 
differential may show neutrophilia and the total cell count may be increased, as a sign of 
immunoactivation (Kinnula and Tukiainen 2004). Most importantly, however, BAL excludes other 
conditions, such as exposure to asbestos and infectious agents. Sedimentation rate and CRP might 
be elevated. Rheumatoid factors and antinuclear antibodies are seen in up to 30% of IPF patients 
(Holgate et al. 1983, Fellrath and duBois 2003). Pulmonary function tests show restriction with 
reduced vital capacity, and/or lowered diffusing capacity for carbon monoxide, and/or reduced 
arterial oxygen pressure (King et al. 2001, Kinnula and Tukiainen 2004). 
 
Conventional chest radiography typically shows bibasilar nodular or reticular infiltrations. HRCT 
appears to be a valuable tool in diagnosing IPF and distinguishing it from other IIPs (Tung et al. 
1993, Johkoh et al. 1999). The HRCT technique with slices of 1-2 mm in thickness and an 
algorithm that maximizes spatial resolution gives detailed images of lung parenchyma. Typical 
features are peripheral reticular opacities, most marked at lower zones, honeycombing is common, 
as well as traction bronchiectasis. Mild ground glass attenuation might also exist. Architectural 
distortion of the parenchyma is often evident. The characteristic radiological features are located 
most typically at lower lobes and peripherally (ATS 2000). HRCT, evaluated by an experienced 
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observer, appeared to distinguish histologically verified UIP in 71% (25/35) of 129 patients with IIP 
(Johkoh et al. 1999). 
 
Figure 2. Typical high resolution 
computed tomography (HRCT) image of  
idiopathic pulmonary fibrosis (IPF) with 
bibasal honeycombing and traction 
bronchiectasis.  
 
 
 
 
 
 
 
 
 
The gold standard in diagnosing IPF is a surgical lung biopsy showing a pattern of UIP. 
International guidelines recommend taking the biopsy if there are no contraindications for surgery. 
It is especially important if a patient presents clinical, physiological, or radiological features that are 
not typical for IPF (Costabel and King 2001, ATS 2002). Surgical lung biopsy, taken with video-
assisted thoracoscopy (VATS) or open thoracotomy, provides tissue samples to distinguish UIP. 
VATS has been shown to be a safe procedure (Bensard et. al. 1993, Sihvo and Salo 2003). 
Transbroncial biopsy does not provide enough tissue for IPF diagnosis (Akira et al. 1993). Typical 
for the histological appearance in UIP is that in areas of normal lung, scattered fibroblastic foci, 
architectural destruction, and honeycombing fibrosis appear randomly (Katzenstein and Myers 
1998, Travis et al. 2000, Flaherty et al. 2001). That is why it is recommended to take multiple tissue 
samples from macroscopically normal appearing lung areas, as well as from the affected lung 
(Flaherty et al. 2001). The interstitial fibrotic foci composed of active proliferating fibroblasts and 
myofibroblasts are thought to be the key features of the active fibrotic process (Selman et al 2001). 
The fibrotic changes show temporal heterogeneity from scattered fibroblastic foci to dense acellular 
collagen. Interstitial inflammation is mild or moderate. The histological changes appear most 
prominently in the peripheral subpleural parenchyma. Areas of normal (or close to normal) lung 
should be seen in tissue samples in order to exclude other interstitial diseases (ATS 2002). 
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Figure 3. Typical features of usual interstitial pneumonia (UIP) in surgical biopsy. Honeycombing, temporal 
heterogeneity and architectural destruction (A), and a fibroblastic focus (arrow) (B) can be identified. 
 
IPF is very often difficult to distinguish from the fibrotic form of NSIP. Biopsy specimens from 
multiple lobes may show patterns of both UIP and NSIP, and these NSIP-like areas could be present 
in the majority of UIP cases (Flaherty et al. 2001, Kazensten et al. 2002). In such cases the 
pathological diagnosis remains UIP and the clinical outcome is similar to that of IPF (Flaherty et al. 
2001, Kazensten et al. 2002).   
 
1.6 Treatment 
 
For decades it has been the tradition to treat IPF patients with corticosteroids and 
immunosuppressive agents. There is, however, no supportive evidence that immunosuppressive 
agents improve survival or the quality of life (Maple et al. 1996, Mason et al. 1999, Selman et al. 
2004). Because of the lack of a more effective therapy, according to the present international 
guidelines of ATS/ERS, combined therapy of corticosteroid and azathioprime, or 
cyclophosphamide should be used for a minumum of 6 months if no intolerable side effects occur. 
The therapy should be carried out only in patients who show objective evidence of continued 
improvement or stabilization of the condition (ATS 2000). During therapy the patients should be 
monitored carefully because of the possible and probable adverse effects (ATS 2000). 
 
Some patients can get symptomatic relief from antitussive agents and opioids (ATS 2000). For 
patients who deteriorate despite optimal medical treatment lung transplantation can be considered 
(ATS 2000). 
 
Despite the use of aggressive treatments, IPF is in the majority of cases a progressive, irreversible 
and fatal disease (Selman et al. 2001, Gross and Hunninghake 2001, duBois and Wells 2001). It is 
A B 
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unlikely that any of the present treatments will improve the prognosis of IPF, and therapies based 
on alternative approaches are needed. The possible targets are to inhibit fibroblast proliferation and 
ECM accumulation, to induce apoptosis of myofibroblasts, and to prevent the epithelial damage or 
to provoke its repair (Selman et al. 2001, Fellrath and duBois 2003). There are plenty of ongoing 
clinical trials based on these alternative mechanisms: pirfenidone inhibits TGF-β-stimulated 
collagen synthesis and decreases the ECM (Raghu et al. 1999), interferon-γ inhibits fibrogenesis 
(Ziesche et al. 1999), N-acetylcysteine is a glutathione precursor that prevents epithelial cell injury 
mediated by oxygen radicals (Behr et al. 1997), captopril inhibits the angiotensin-converting 
enzyme that induces AEC apoptosis (Uhal et al. 1998), and bosentan is a endothelin-1- inhibitor 
that is one of the cytokines associated with fibroblast proliferation (Fellrath and duBois 2003, 
Selman et al. 2004). 
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2. GENE MAPPING OF COMPLEX DISEASES 
 
2.1. General 
 
Using gene mapping approaches in the identification genes causing simple Mendelian diseases has 
become a straightforward process. When a defect in a gene is detected only among patients and 
never among healthy controls the connection between the gene and the disease is easy to establish. 
Complex diseases do not follow classic Mendelian inheritance, but involve multiple genetic and 
environmental determinants. Susceptibility alleles are found both among patients and controls (low 
penetrance), but the frequencies are different. The disease-predisposing allele is likely to result in 
disease together with favourable environmental and/or other genetic factors. With different 
environmental and/or genetic factors the allele is carried by unaffected as well. The incomplete 
correspondence between a single allele and the disease makes both the mapping and the 
identification of the disease-causing genes difficult. A mutation in a gene can result in causing a 
disease in various ways. Only one amino acid change in the product of the gene can alter the 
function. There is increasing evidence that identified polymorphisms not only in coding, but also in 
non-coding sequences, can change expression levels and splicing (Pagani and Baralle 2004). The 
expression levels can also be contolled by several trans-acting factors, such as transcription factors 
that can be located far from the gene (Pastinen and Hudson 2004). During the recent years, genes 
and molecular genetic mechanisms responsible for complex diseases, such as in asthma (Laitinen et 
al. 2004), hyperlipidemia (Pajukanta et al. 2004), and psoriasis (Asumalahti et al. 2000), have 
successfully been identified. 
 
The methods of locating susceptibility genes are based mainly on either linkage or association 
approaches. The goal of a linkage study is to identify chromosomal loci that are present in affected 
family members more often than is explained by Mendelian segregation; the alleles are used as 
tools for assessing the linkage properties of these loci. In association studies particular alleles are 
the subject of study, and might even be the cause of the phenotype. Association is a population 
property and can be assessed in unrelated individuals (Ewens and Spielman 2001).  These two 
approaches can completement each other: linkage studies can bring up hypotheses that can be 
verified in larger population- or case-control association studies. 
 
There are several aspects concerning the difficulties in mapping complex diseases. One genotype 
can lead to different phenotypes or different genotypes can lead to identical clinical outcomes. All 
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individuals with a predisposing allele may not manifest the disease, in the case of incomplete 
penetrance. Individuals without the predisposing allele may also manifest the disease, termed as 
phenocopies (Lander and Schork 1994). Polygenic inheritance makes mapping more difficult, 
because some diseases require inherited susceptibility alleles in multiple genes, as a single locus is 
alone incapable of causing the disease. 
 
The number of disease-causing alleles in every gene varies plenty, as do the allele frequencies. If a 
disease-causing allele is very frequent in a population, it may be difficult to distinguish its` 
association to the disease. Those genes with only a few harmful alleles can be identified more 
easily. According to the Common Disease/Common Variant (CD/CV) hypothesis common diseases 
are due to the alleles with relatively high frequencies (Reich and Lander 2001). Allelic diversity is 
also thought to be similar for common and rare diseases (Hartl and Campbell 1982). In real 
populations, however, there tends to be multiple disease-predisposing alleles for rare diseases 
(Reich and Lander 2001). 
 
The distances between observed loci are measured in genetic units, centimorgans (cM). One cM 
corresponds to the distance within which one recombination is supposed to occur in every 100 
meioses and corresponds approximately to a physical length of one megabase (Mb) of DNA 
(Thompson et al. 1991). When alleles on the same chromosome tend to occur together more often 
than expected under random segregation they are said to be in linkage disequilibrium (LD) 
(Terwilliger and Ott 1994). 
 
2.2 Linkage analysis 
 
In order to find linkage beween IPF and disease-predisposing loci it is crucial to define the proper 
phenotype of the affected family members and to identify multiplex families with linkage 
information. In some diseases, such as IPF, with the late onset, and short survival after diagnosis, 
the recruitment period is extremely short. Family members may have died before the disease was 
manifested, or their symptoms have been interpreted as other than IPF before the improved 
diagnostic techniques and the present classification were available – both examples result in 
ignoring the true familiality, and excluding informative families.  
 
By means of positional cloning, disease-predisposing genes are identified purely due to their 
chromosomal location, without concern for their function. Botsein et al. (1980) recognized naturally 
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occurring DNA sequence variations, simple tandem repeats (also called microsatellites). These 
occur in mammalian genomes at fairly regular intervals, and can be used as genetic markers in gene 
mapping strategies (Weber and May 1989). 
 
Linkage analysis tries to locate chromosomal regions (containing a disease-predisposing gene) by 
detecting marker loci and disease phenotype that segregate together. Two-point linkage analysis 
shows whether a particular allele and the disease have a tendency to be co-inherited from parents to 
offspring, which could indicate a short distance between the allele and disease-causing gene 
(Terwilliger and Ott 1994). Multipoint analysis gathers information from multiple markers 
simultaneously to estimate whether an allele at a given point is shared identical-by-descent (IBD) 
(Kruglyak and Lander 1995, Ott 1996), and thus tests for linkage to an extended chromosomal 
region rather than to a single point. 
 
Linkage analysis can be performed by either a parametric or a non-parametric approach. Parametric 
linkage analyses estimate the recombination fraction (equivalent to genetic distance when small) 
between a disease and marker loci when the mode of inheritance is known (Ott 1996). In the case 
the mode of inheritance is known, the statistical power is generally higher than with non-parametric 
linkage analysis (NPL). For NPL analysis the mode of inheritance does not need to be determined. 
The simplest NPL analysis is estimating whether affected siblings share an IBD allele more often 
than expected according to Mendelian transmission (Terwilliger and Ott 1994). The method is 
nowadays mostly used as an extended version, an extended relative pair analysis, and it takes into 
account all of the affected family members instead of the sibpairs. NPL method compares the alleles 
shared by affected individuals, and the unaffected individuals are ignored. NPL uses all the 
genotype data collected from all available pedigree members, and it computes the probable IBD 
statuses also for missing genotypes (Kruglyak et al. 1996).  
 
The complex inheritance of diseases such as IPF offer challenges. Some individuals who inherit a 
predisposing allele do not manifest the disease (incomplete penetrance), while others who have not 
inherited the allele may anyhow get the disease due to environmental or random causes 
(phenocopy). Genetic heterogeneity, where a chromosomal region may segregate with the disease in 
some of the families, but not in others, may hamper gene mapping.  A disease-causing allele is hard 
to map if it occurs at high frequency in the population.  One gene may interfere with the expression 
of another gene located at a different locus (epistasis), and multiple, often seemingly unrelated, 
physical effects may be caused by a single altered gene or a pair of altered genes (pleiotropy) 
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(Lander and Schork 1994, Tabor et al. 2002, Risch 2000). It is therefore crucial to gather all the 
possible available marker and genotype data from the pedigrees, which is computationally 
demanding. A widely used computer package is GENEHUNTER (Kruglyak et al. 1996). The 
package can simultaneously analyse the data with parametric and non-parametric methods, conduct 
non-parametric two-point and multipoint analyses, determine the information content for each 
marker, re-construct haplotypes, and analyse affected sibpairs (Kryglyak et al. 1996, Ewens and 
Spielman 2001).  
 
The statistical measurement in parametric analyses is the logarithm (log10) of odds (LOD) score. It 
is a ratio of the likelihoods of 1) linkage between a locus and a marker at a certain recombination 
fraction (θ) compared to 2) no linkage (θ = 0.5) (Terwilliger and Ott 1994). The recombination 
fraction (θ) measures the extent of linkage between two loci, i.e. the probability of a recombination 
occurring between two loci. The most likely θ gives the highest LOD score (Pawlowitzki et al. 
1997). Non-parametric linkage can be analysed by two additional tests: Spairs and Sall, which are 
based on IBD statuses. Spairs consideres all affected sibpairs, while Sall consideres all family 
members, with the assumption that if many affected relatives share the same allele IBD, linkage to 
the disease-causing allele is more likely than in the case of only affected siblings sharing it. These 
calculations result in NPL scores NPLpairs and NPLall, very often presented as Zpairs and Zall 
(Kruglyak 1996). 
 
Lander and Kruglyak (1995) suggested significance criteria for LOD scores in complex diseases. 
The criteria are valid only in perfect data sets with complete pedigrees, and with 100% successful 
genotypes – the criteria that correlate poorly with real data sets. A LOD score of 3.3 or higher is 
considered as significant evidence for linkage, and a LOD score >1.9 for suggestive linkage. The 
performance of NPLall is roughly comparable to that of LOD score analysis under the correct 
inheritance model. NPLall appears to be a non-parametric pedigree-analysis method that loses 
relatively little power when compared with the best parametric method (Lander and Kruglyak 
1995). Altmuller et al. (2001) reviewed 101 genome-wide scans in complex human diseases. Of 
these, 67 showed no significant linkage according to the categories proposed by Lander and 
Kruglyak (1995), suggesting that significant linkage is hard to find in genome-wide scans in 
complex diseases. Some concern has been raised whether the thresholds should be lower among 
genome scans in complex diseases (Altmuller et al. 2001, Wiltshire et al. 2002, Sawcer et al. 1997, 
Göring et al. 2001).  Therefore, a method of choice to estimate the power to detect linkage in 
complex diseases is simulation. Randomly generated genotypes, real marker densities, and true 
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pedigree structures are simulated N times. When the considered NPL score exceeds the NPL score 
that is observed once per genome scan at random it is proposed to show suggestive linkage, and 
significant linkage is obtained when the NPL score exceeds the one observed once per every 20 
genome scans at random (Lander and Kruglyak 1995, Laitinen et al. 2001). Wiltshire et al. (2002) 
simulated an experimental data set with a 10 cM marker map and 15% missing genotypes, and 
found that an independent region showing evidence for linkage (IRL) with a LOD score of 1.51-
1.55 is expected to occur only once by chance. They proposed this locus-counting method (IRLs) as 
an additional method for evaluating the results of genome scans on complex diseases. 
 
2.3 Association analysis 
 
Association studies are based on consideration of whether a genetic polymorphism is overpresented 
(positive association) or underpresented (negative association) in the studied phenotype compared 
to a control population (Lander and Schork 1994, Baur and Knapp 1997). Associations can be 
performed for any DNA polymorphism, but they are more meaningful when applied to functionally 
significant variations in genes having a clear biological relation to the disease. Multimarker 
haplotypes are more informative than single alleles. In the case where true association has been 
detected, it can be due to 1) an allele actually being the disease-causing allele, 2) an allele being in 
linkage disequilibrium with the disease-causing allele, or 3) an artifact of population admixture: any 
trait present frequently in an ethnic group shows positive correlation with any high frequency allele 
(false positive finding) (Lander and Schork 1994). Because of the later the selection of a control 
group is crucial. While studies are performed in relatively homogenous populations, within an 
ethnic group, the control population should represent the same ethnic origin (Lander and Schork 
1994, Risch 2001). Population stratification can be partly avoided by using non-affected family-
based controls (Lander and Schork 1994, Risch 2001). The affected and non-affected family 
members alike carry background hereditability and experience similar environmental factors. 
Therefore, an observed association to the disease is most likely to be true positive. Sampling 
families of varying ethnicity is advantageous to enhance evidence of causality as well as to identify 
genetic and/or environmental modifying factors (Risch 2000). Consistent replications of the 
association in assorted studies with different populations strengthen the evidence of causality.  
 
Improved techniques for genotyping polymorphisms and extended computational possibilities have 
made it possible to look for differences in genetic variants throughout the entire genome between 
affected individuals and controls. Whole-genome linkage disequilibrium mapping is based on the 
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fact that some of the polymorphisms and disease-predisposing alleles are located nearby each other 
(Kruglyak 1999). LD varies depending on the genomic region and population history (Wright et. al. 
1999). The average LD distance rarely extends beyond around 3 kb in the general population, 
however, it can extend further in young founder populations (Kruglyak 1999, Wright et. al, 1999). 
The markers of choice are biallelic single nucleotide polymorphisms (SNPs) because they are 
extremely numerous (approximately 3 million SNPs, one in every 1 kb), are expected to exist in the  
human genome, they have low mutation rates, and analysis is quite easy to automate. Current 
estimates of the number of SNPs needed for whole-genome association studies vary considerably, 
from 100 000 to 500 000 (Kruglyak 1999, Palmer and Cardon 2005). Whole-genome LD mapping 
is thus far financially available for very few researchers, but with improving technology it will 
hopefully be easier to access. The interest in average LD lengths has been, however, replaced by 
awareness of special LD patterns (Cardon and Abecasis 2003). It seems that the genome is 
composed of a series of high LD regions (blocks) flanked by very low LD regions (recombination 
hotspots) (Cardon and Abecasis 2003).  Preliminary results suggest that three to five haplotypes can 
account for 90% of all haplotypes in the human population, and each haplotype block is on average 
22-44 kb long; shorter in populations originated from Africa than in the other examined samples 
(Daly et al. 2001, Gabriel et al. 2002). These blocks could be detected with few markers and less 
money. The ongoing haplotype mapping project (HapMap) aims to characterize patterns of LD in 
the human genome  (Gabriel et al. 2002, www.hapmap.org).  
 
Association studies with candidate genes have been widely used in complex diseases, but the results 
have been conflicting (Risch 2000, Tabor et al. 2002). Considering the location and function of each 
polymorphism, along with more information about LD patterns and potential haplotypes, and with 
the knowledge of the sequences and functions of the candidate genes, selecting precise candidate 
genes and variants to perform association studies seems more promising (Risch 2000, Tabor et al. 
2002). 
 
2.4 Characteristics of the Finnish population 
 
The majority of the genes of the Finnish population are thought to originate from a small number of 
founders who immigrated from the south around 2000 years ago (Lahermo et al. 1999, Peltonen et 
al. 1999).  The population grew very slowly, at the beginning of the 18th century there were 
approximately 250 000 Finns. After that the population expanded rapidly, today being 5,2 million 
inhabitants. 
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Until the reign of Gustavus of Vasa (1523-1560), most of the Finns lived on the southern and 
western coastlines, in the early settlement area. During that reign people of the early settlement, 
mostly farmers from southern Savo, moved to eastern, central, and northern parts of Finland, to the 
late settlement area. The immigrated groups lived for centuries in subisolates. Until the Second 
World War many of these northeastern settlements consisted of descendants of 40-60 founding 
families (Varilo et al. 2000). During the immigration in the 16th century the national system of 
parish and tax records was established, which still works as a magnificent tool to solve pedigree 
structures and to trace common ancestors (Peltonen et al. 2000). 
 
During immigration the Finns have gone through multiple genetic bottlenecks. Because of the small 
number of founders the population of Finland has experienced genetic drift that favored retention of 
some genes and removed others. Genes with allele frequencies of a few per cent showed more than 
10-fold differences among seven communities in a study by Nevanlinna (1972). For common 
alleles, the overall frequencies in Finland are similar to other European countries, but very rare 
alleles have been almost totally lost from most subisolates (Kere 2001).  
 
Since Norio (1966) brought up the genetic background of congenital nephritic syndrome, at least 36 
monogenic disorders have been successfully identified among Finns (Norio 2003). Complex traits 
are not inherited according to Mendelian transmission, and their phenotypes are more diverse. 
Many complex diseases tend to manifest at older ages, and allow the disease-causing allele to be 
transmitted, leading to the existence of even dominant disease alleles in pedigrees. When a disease 
can be caused by each of several rare alleles, poor genetic diversity in isolated population is 
advantageous, as has been shown in nonpolypotic colon cancer, combined hyperlipidemia, and long 
QT syndrome (Peltomäki 1993, Vuorio et al. 1997, Piippo et al. 2000).  
 
After a founder mutation has been introduced into a population, in young populations fewer 
crossovers have influenced the flanking chromosomal regions, and chromosomes in individuals 
include longer regions of common ancestral chromosomes. This has been regarded as advantageous 
in using population isolates for mapping. The levels of LD between common markers close to each 
other, however, do not show remarkable differences between Finland and other countries. The LD 
patterns are preserved only over short (<1 cM) distances when comparing alleles of linked loci 
within randomly selected individuals from the sub-population of Kuusamo, and across Finland 
(Varilo et al. 2000). On the other hand, in isolated founder populations affected individuals are 
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obviously related to each other and their predisposing alleles are likely to be IBD instead of 
identical by state (IBS). Because the affected individuals most likely have inherited a rare (disease-
predisposing) allele from a common ancestor, there may be long, conserved haplotypes adjacent to 
rare disease alleles, and associations with the surrounding markers are expected, as well as higher 
levels of LD.  The extent of the LD around a disease gene reflects the age of the mutation, and the 
extremes of LD intervals vary in Finland from 11 cM to 13 cM (Höglund et al. 1995, Varilo et al. 
1996, Peltonen et al. 1999).  
 
Because of the genetic bottlenecks, random drift, and the high levels of LD over long chromosomal 
regions, the genetic and haplotype diversity is far lower in population isolates such as Finland, 
which provides advantageous conditions for the identification of disease alleles. 
 
In addition to genetic homogeneity, cultural homogeneity favors performing genetic studies in 
Finland. Diagnostic criteria across Finland are extremely uniform. Patients are entitled to 
compensation for medication through a nationwide institution, The Social Insurance Institution of 
Finland. The desicion for compensation is based on reports of diagnostic criteria that have to be 
fulfilled according to the ICD-10 criteria. The diagnoses are registered in hospital discharge 
records. The standardized quality of health care and health care registers make diagnoses relatively 
comparable and reliable. 
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3. GENETICS OF IPF 
 
Rare, late onset diseases are a challege for linkage studies. IPF manifests often after the age of 60 
and leads to death within a couple of years. Thus genotyping of the parents of the probands is very 
often impossible, and even the availability of DNA from all affected siblings is difficult. To find 
families with enough linkage information to identify meaningful linkage has been an obstacle to 
performing genome screens. IPF is the most lethal form of IIPs and still, under the new 
classification era, many IIPs are misdiagnosed as IPF. Most of the studies concerning the genetics 
of IPF are case-controlled, association-based studies on sporadic cases, using microsatellite or SNP 
analysis of candidate genes.  
 
The only published linkage study attempting to locate a chromosomal region for IPF was performed 
on chromosome 14 (Loyd 2003). An interest in chromosome 14 was aroused due to two reports 
which showed an increase in the frequency of Z and S alleles of the α-1-antitrypsin gene among IPF 
patients (Geddes 1977), and an association between IPF and immunoglobulin Gm allotypes (Musk 
et al.1986), both genes encoded on chromosome 14. Therefore, a collaborative study was performed 
with 70 individuals from 11 families using 14 markers distributed across chromosome 14 to 
establish or exclude linkage. All two-point and multipoint LOD scores were either negative or near 
zero suggesting that with this data set linkage to chromosome 14 can be excluded (Loyd 2003). 
 
3.1 IPF in families 
 
The most convincing evidence for genetic predisposition in the pathogenesis of IPF is the existence 
of multiplex families, i.e. families with more than one affected member. Peabody and Hayes (1950) 
presented an identical twin pair, whose symptoms started within 16 months of each other and were 
diagnosed as having IPF. MacMillan used the term familial pulmonary fibrosis already in 1951 to 
describe a mother and her adult daughter who both died from fibrotising lung disease. In 1965, 
Bonnani and collagues described a family with eight affected family members, with ages at death 
ranging from 38-52 years. Since then many anecdotal cases of familial idiopathic pulmonary (FPF) 
fibrosis have been reported (Javaheri et al. 1980, Bitterman et al. 1986, Uchiyama et al. 1997). 
Twenty-five families with two or more affected family members were identified in the United 
Kingdom through a questionnaire mailed to respiratory physicians (Marshall et al. 2000). 
Altogether 67 individuals were diagnosed with IPF; the diagnoses were confirmed in 32% of the 
cases with a biopsy, although this occurred prior to the recent diagnostic criteria. They calculated a 
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prevalence of 1.34/million for FPF. In order to define clinical features of FPF, Lee and collagues 
(2005) described 15 families with at least two affected family members. They compared the clinical 
features and survival with nonfamilial cases, and found no differences. Steele and collagues (2005) 
recently reported 111 families with two or more cases of IIP, IPF among them.  
 
Although the model of inheritance is not clear, the autosomal dominant model with varying 
penetrance has been proposed (Marshall et al. 1997, Marney et al. 2001). Most of the described 
pedigrees demonstrate vertical transmission from a parent to an offspring (Bonnani et al. 1965, 
Bitterman et al. 1986, Uchiyama et al. 1997, Marshall et al. 2000, Thomas et al. 2002, Lee et al. 
2005), confirming this model. Sex-linked inheritance was excluded by reports of father-son 
transmissions (Koch 1965, Adelman 1966). According to recently published reports, patients within 
the same family have been affected by distinct subtypes of IIP, mostly IPF and NSIP. This may 
reflect that the same genetic mechanisms may result in diverse interstitial responses  (Thomas 2002, 
Steele 2005) 
 
3.2 Candidate genes 
 
Genes that have been proposed as candidate genes for IPF are categorized based on their possible 
functional role in the pathogenesis of IPF. Polymorphisms in the genes have often been amino acid 
changes that could alter the protein function. The genetic studies of IPF have mostly been 
association studies with case-control designs. The results have been predominantly either 
conflicting or proposed associations have not been confirmed. On the other hand, candidate genes 
cannot be ruled out based on negative results when only some of the polymorphisms in a gene have 
been studied, or when studies have been performed with one distinct population or with a small 
number of individuals.  
 
3.2.1. Immune response genes 
 
The earliest studies focused on a possible association between human leucocyte antigen (HLA) 
genes of the major histocompatibility complex (MHC) and IPF. Some association was detected 
between an increase of the serologically-detected HLA-DR2 antigen and IPF (Libby et al. 1983), 
but the descriptions of the radiological findings suggest the patients also represented other forms of 
IIPs.  Fulmer and collagues (1978) detected no differences in 35 serologically detected HLA A and 
B antigens between IPF patients and controls. Only very recently, MHC polymorphisms were 
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evaluated with modern gene technology. Falfan-Valencia and collagues (2005) studied the HLA-B, 
-DRB1, and -DQB1 loci in a cohort of 75 IPF patients and 95 controls. Three haplotypes were 
significantly increased in IPF: 1) HLA-B*15-DRB1*0101-DQB1*0501 (OR=10.72, CI=1.43-
459.6); 2) HLA-B*52-DRB1*1402-DQB1*0301 (OR=4.42, CI=1.21-24.1); and 3) HLA-B*35-
DRB1*0407-DQB1*0302 (OR=4.73, CI=1.53-19.5). BAL cells collected from patients with these 
haplotypes showed reduced epithelial growth rates, and caused epithelial cell apoptosis. Their 
findings suggest that some MHC polymorphisms cause susceptibility to IPF. 
 
TNF-α and Interleukins 1 and 6 (IL-1, IL-6) are proinflammatory and fibrogenic cytokines (Pan et 
al. 1996, Chambers et al. 2003). Whyte and collagues (2000) compared 88 IPF patients from 
England and 61 patients from Italy to 191 controls to detect SNP polymorphisms in the IL-1 
receptor antagonist (IL1RN), and Tumor Necrosis Factor-α (TNF-α) genes. The authors suggest that 
carrying the IL1RN allele +2018T and the non-coding TNF-α -308A allele is associated with 
increased risk of developing IPF. The association of the TNF-α -308A allele with IPF was 
confirmed by Riha et al. (2004) in their study of 22 IPF patients, while Pantelidis and collagues 
(2001) were unable to confirm the association. They screened altogether 12 SNPs in the TNF-α, 
lymphotoxin-α, TNF-receptor 2, and interleukin-6 (IL6) genes in 74 IPF patients from England and 
201 population-based controls. However, the authors suggested that the cocarriage of intronic 
SNPs, allele 4GG in IL6, and allele 1690C in TNF-R2 were increased among IPF patients 
compared to the controls. Further, the GG genotype in intron 4 of IL6 was found to be 
independently associated with lower diffusing capacity for carbon monoxide levels. No association 
was observed between IPF and the studied polymorphisms by Hutyrova and collagues (2002), who 
explored the polymorphisms in the IL1α, IL1β, and IL1RN genes that are clustered on chromosome 
2q13-21. The study population consisted of 54 IPF patients, 95 sarcoidosis patients, and 199 
controls from the Czech Republic, all of west Slavonic ancestry.  
 
Cytokine mediators that provoke T cell-response towards Th2 predominance act as functional 
candidate genes for IPF. Associations between the SNPs C1188 in the IL12 gene, on chromosome 
5q31-33, that has been proven to cause a functional change, and G5644 in the IFN-γ gene, on 
chromosome 12q14, with susceptibility to IPF were studied. Seventy-three patients and 157 
population-based controls carried similar allele frquencies (Latsi et al. 2003).  
 
Intra-alveolar activation of the coagulation system due to reduced fibrinolytic fuction has been 
suggested to play a role in the pathogenesis of IPF (Fujimoto et al. 2003). The frequencies of 
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polymorphism 4G/5G in the plasminogen activator inhibitor-1 promoter, encoded on chromosome 
7q21-22, did not differ between 62 patients with IPF and controls (Kim et al.  2003). 
 
The Complement Receptor 1 (CR1) gene (known also as the complement component 3b/4b receptor 
or C3-binding protein) is located on chromosome 1q32. CR1 is expressed in different cells, 
including phagocytes, lymphocytes, and dendritic cells (Fearon and Wong 1983), but mainly on the 
surface of erythrocytes (Siegel et al. 1981). The primary function of CR1 is mediating the 
adherence of target molecule coated with the complement components C3b and C4b, and their 
transport to the reticuloendothelial system, the spleen and liver, to be destroyed (Cornacoff et al. 
1983, Davies et al. 1992). Immune complexes that escape the reticuloendothelial system can in turn 
increase tissue damage associated with many immune diseases. 
 
A total of 11 nonsynonymous polymorphisms in the coding sequence of CR1 have been reported 
(http://www.ncbi.nlm.nih.gov/SNP). The substitution C5507G in exon 33 leading to an amino acid 
change from proline to arginine (Pro1827Arg) has been reported (Zorzetto et al. 2002). The 
polymorphism creates a potential cleavage site for trypsin-like proteases that allow its accelerated 
proteolysis and, in return, decrease the activity of the complement (Herrera et al. 1998). 
Pro1827Arg has been associated previously with two parenchymal pulmonary diseases, sarcoidosis 
and IPF, among Italian patients (Zorzetto et al. 2002, Zorzetto et al. 2003). Arg1827 homozygosity 
was significantly more common in patients with sarcoidosis (OR=3.1, 95%CI=.5-6.7) and IPF 
(OR=6.2, 95%CI=2.2-18.4) than in control subjects or COPD patients.  
 
3.2.2 Genes in biochemical defence  
 
Lungs are directly exposed to high levels of environmental oxidants, such as pollutants, ozone, 
fibers, cigarette smoke, and radiation, as well as hyperoxia (Kinnula and Crapo 2003). In these 
circumstances several endogenous enzymes and reaction pathways can be activated to generate 
reactive oxygen species (ROS). Reactive nitrogen species (RNS) can be generated in parallel, when 
also endogenous nitric oxide (NO) is present. Constitutive and inducible forms of NO are widely 
expressed in lungs (Kinnula et al. 1995, Kinnula et al. 2005). Although ROS and RNS are essential 
for normal physiological functions, such as taking a part in phagocytosis (Ottonello et al. 1995), 
mediating smooth muscle relaxation (Dupuy et al. 1992), and modulating pathways in cell 
signalling (Thannickal and Fanburg 2000), they are extremely potent in causing nonspecific damage 
to cells and ECM (Kinnula and Crapo 2003). 
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Antioxidants defend against ROS and RNS by either enzymatic or nonenzymatic ways (Bowler and 
Crapo 2002). Extracellular superoxide dismutase (ECSOD) is an antioxidative enzyme belonging to 
a family of superoxide dismutases (SOD). It is expressed in various tissues, highly in lung, and is 
abundant in airway epithelial and vascular endothelium, and especially in the extracellular matrix 
(Marklund 1984, Folz and Crapo 1994, Oury et al. 1996). ECSOD is the major enzyme capable in 
dismutating superoxide radicals into hydrogen peroxide and oxygen in the ECM (Fattman et al. 
2003, Kinnula and Crapo 2003). 
 
Imbalance between oxidants and antioxidants in the lung provokes oxidative stress. The importance 
of ESCOD against oxidative injury has been confirmed both in transgenic (Bowler et al. 2002, Folz 
et al. 1999, Ghio et al. 2002) and knockout mice (Carlsson et al. 1995, Fattman et al. 2003), thus 
suggesting that ESCOD may be one of the major enzymes against oxidant-mediated parenchymal 
lung injury, such as that seen in IPF. 
 
Surfactant protein C (SP-C) is a membrane protein expressed by epithelial cells in the lung. Mature 
SP-C maintains a biophysical surface activity and may also protect the surfactant film layer. The 
SP-C gene is located on chromosome 8p21. Multiple heterozygous alleles in the SP-C gene have 
been reported in association with interstitial lung diseases (Nogee et al. 2001, Nogee et al. 2002). 
One of these is a single nucleotide change T128A resulting in an amino acid change from leucine to 
glutamine (Leu188Glu). There is some evidence that the Leu188Glu mutation may cause 
misfolding and trapping of proSP-C preventing delivery to distal secretory components, and this 
could eventually lead to type II cellular damage (Thomas et al. 2002). The Leu188Glu mutation was 
studied in a large kindred of 97 individuals; 14 of them were affected, 11 adults and 3 children. All 
the children were diagnosed as NSIP verified with a biopsy, and all the adults were diagnosed as 
UIP, 6/11 had biopsy verification. The Leu188Glu mutation was detected among all the affected 
individuals, but in only two non-affected family members (Thomas et al. 2002). The presence of 
two different pathologic diagnoses in one kindred all sharing the same mutation might reflect 
different pathogenesis in the children in comparison with the adults, or the phenotypes may 
potentially overlap. Two affected brothers with probable IPF were sequenced to screen for the 
reported SP-C gene mutations, but none was observed (Yoshioka et al. 2004). The SP-C gene was 
also sequenced in 89 sporadic IPF patients and 46 NSIP patients (Lawson et al. 2004). Ten SNPs 
were revealed among IPF patients, but in none of the controls. Only one SNP in a single patient 
created an amino acid change, and one intronic SNP suggested a potential splicing site. The authors 
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concluded that according to their findings mutations in the SP-C gene do not explain the 
pathogenesis of IPF in the majority of sporadic cases. 
 
Zuo and collagues (2002) used cDNA microarrays to identify candidate genes. They collected a 
pool of RNA obtained from five patients with pulmonary fibrosis; three had a histologic verification 
of IPF, one also had rheumatoid arthritis and one had Sjögren`s syndrome. Controls consisted of 
eight individuals who did not suffer from parenchymal disease. An array with 7129 genes revealed 
164 genes with significantly different expression profiles between the two groups. The expression 
was increased for genes encoding smooth muscle proteins, immunoglobulins, and some 
complement factors, and genes encoding proteins that are involved in ECM formation, degradation, 
and signaling. Among all, matrilysin (matrix metalloproteinase 7, MMP-7), encoded on 
chromosome11q21-22, was the most up-regulated gene. They continued to study MMP-7 in an 
experimental model and administered bleomycin to the lungs of MMP-7 knockout mice, and their 
wild-type controls. Two to three weeks later, the histologic changes were milder among the MMP-
7-knockout mice compared to the changes in wild-type controls. They suggested matrilysin as a 
mediator of pulmonary fibrosis. 
 
3.3 Mouse models 
 
Plenty of mouse models have been used in order to clarify the steps of the fibrotic cascade. Fibrosis 
has been introduced to the mice by several ways. Intratracheal instillation of bleomycin has been 
widely used. Other ways to induce fibrosis to mice are irradiation and administration of various 
fibrogenic agents. These models do not, however, represent the model of the pathogenesis of IPF, as 
it is understood today. The models include known etiological factors, inflammation precedes 
fibrosis, and, in mice as in humans, bleomycin- induced fibrosis responds quite well to steroid 
treatment, unlike in IPF. 
 
A strain-dependent variability in the response to fibrosis-inducing agents has been recognized. 129J 
mice exhibit a reduced fibroproliferative response compared to C57BL/6 mice, which develop clear 
fibroblastic foci at the sites of injury. 129J mice are regarded as fibrosis-resistant and C57BL/6 
mice as fibrosis-prone strains (Marshall et al. 1997, Brody et al. 2002). The 129J strain was crossed 
to the C57BL/6 strain, and the offspring were subsequently backcrossed to the inbred 129J 
founders. The backcross produced a generation of which approximately 25% carried a phenotype 
that, similarily to 129J, was protected from fibrosis. In both original strains the TGF-β gene was  
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overexpressed, which caused a significantly lower fibroproliferative response in 129J mice 
compared with C57BL/6 mice. Both experiments suggest that 129J mice carry a gene or a cluster of 
genes that protect them from the development of fibrosis, but what the gene/s is/are, is unknown 
(Warshamana et al. 2002).  
 
Several transgenic or knockout mice have been developed in order to identify genes that could play 
a role in the pathogenesis of lung fibrosis. TGF-α, 5-lipoxygenase-derived leucotriene, PAI-1, or 
nuclear factor erythroid 2-related factor knockout mice developed significantly less lung fibrosis 
after being exposed to bleomycin than did the wild-type mice (Madtes et al. 1999, Cho et al. 2002, 
Peters-Golden et al. 2002, Chuang-Tsai et al. 2003), whereas the knockout for cyclo-oxygenase-2 
led to increased lung fibrosis (Bonner et al. 2002). Overexpression of Smad7 protein in mice led to 
suppression of type I procollagen and reduced hydroxyproline content in lung tissue, and the mice 
did not develop fibrosis after bleomycin treatment (Nakao et al. 1999). Mice with overexpressed 
ET-1 developed progressive pulmonary fibrosis with accumulation of ECM proteins, and 
recruitment of inflammatory cells (predominantly CD4-positive cells) (Hocher et al. 2000).  
 
Th1-biased C57BL/6 mice and Th2-biased DBA/2 mice were exposed to bleomycin either once or 
three consecutive times (Chuang-Tsai et al. 2003). Bleomycin induced a Th2-like environment in 
both strains. Fibrosis was detectable only after multiple exposures in Th2-biased DBA/2 mice. 
When Th1-biased C57BL/6 mice were knocked out from endothelial nitric oxide synthetase (which 
protects endothelial cells from oxidative injury), the similar prolonged fibrosis after multiple 
exposures was present. These experiments indicate that the fibrotic cascade is complex and can be 
determined by a number of genetic, and also environmental, factors (Chuang-Tsai et al. 2003). 
 
Mice models have also been used to study gene expression profiles using cDNA microarray 
techniques. Munger and collagues (1999) described a mouse strain (129) that develop inflammation 
but not fibrosis in response to bleomycin. The strain had a null mutation of the epithelial-restricted 
integrin β6-subunit gene (β6-/-). The mice were exposed either to bleomycin or saline, and gene 
expression of these β6-/- mice was compared to that in wild-type mice. The expression pattern of 
approximately 6 000 genes and ESTs were analysed simultaneously (Kaminski et al. 2000). A 
dramatic increase of expression among wild-type mice compared to the β6-/- mice was found in a 
cluster of genes that are involved in the formation of the ECM, regulate responses to the ECM, and 
are induced by DNA damage, such as p21. Quantitative comparison among these genes revealed 
even higher expression response of osteopontin, tenascin-C, tropoelastin, and heme-oxygenase. 
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Macrophage-restricted metalloproteinase expression was increased more than 20-fold in β6-/- mice 
compared to wild-type mice. The identified group of genes might play a role in the fibrotic process, 
as may the epithelial-restricted integrin β6-subunit itself. 
  
A genome-wide scan has been performed in the C57BL/6J mice strain susceptible to fibrosis 
(Haston et al. 2002). The mice were given whole lung irradiation and the mice which developed 
histologically verified fibrosis were genotyped. The screen was performed with 154 markers with a 
mean intermarker distance of 10 cM. The data set revealed regions with LOD scores > 2.8 on 
chromosomes 1, 6, 17, 18, and 19. The study group had previously identified an association of the 
fibrotic phenotype with a marker on chromosome 17 (Haston and Travis 1997). Combining the two 
studies they concluded that on chromosome 17 there is a fibrosis susceptibility locus that includes a 
universal ´fibrotic` gene. Candidate genes mapping to that region in the mouse include TNF, 
manganese superoxide dismutase, plasminogen, and p21. In genomic comparisions, this linkage 
region matches with regions on human chromosomes 4p16 and the HLA-system on chromosome 
6p. 
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AIMS OF THIS STUDY 
 
1. To evaluate the prevalence of idiopathic pulmonary fibrosis in Finland according to the novel 
ATS/ERS 2000 international diagnostic criteria. 
 
2. To evaluate the prevalence of familial idiopathic pulmonary fibrosis in Finland. 
 
3. To identify novel candidate genes for idiopathic pulmonary fibrosis by a genome-wide scan and 
positional cloning. 
 
4. To verify whether polymorphisms Pro1827Arg of the CR1 gene and Arg213Gly of the ECSOD 
gene, that functionally may be significant in the pathogenesis of the disease, are associated with 
idiopathic pulmonary fibrosis among Finnish patients. 
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MATERIALS AND METHODS 
 
1. Patient selection 
 
1.1 Identifying IPF patients 
 
To identify all the IPF patients in Finland, we contacted all pulmonary clinics (N=29) in Finland 
during the years 1997-1998. Hospital databases were screened with the diagnosis J84.1, i.e. 
alveolitis fibroticans idiopathica in accordance with the ICD-10 classification. To evaluate as many 
patients as possible representing different parts of Finland, we selected all five university hospitals, 
the two largest central hospitals, and the largest regional hospital. To reconfirm the diagnosis we 
reviewed 50% of the medical records. In four central hospitals and in one regional hospital a local 
specialist in pulmonary medicine confirmed the diagnosis. For the rest of the hospitals (N=16) the 
number of IPF patients was extrapolated using statistics from the evaluated hospitals. 
 
We mailed a questionnaire to all the still living patients identified by the primary screen (N=1212). 
In the questionnaire we asked whether they have or have had other affected family members and for 
the names and birthplaces of their parents and grandparents. We received 675 (56%) replies. From 
those patients (N=88) who reported an affected family member, we asked for more detailed 
pedigree information and with their permission examined their medical records. A familial case of 
IPF was confirmed when the medical data showed that both the proband and his or her affected 
family member fulfilled the diagnostic criteria. By using the Finnish church records we traced back 
3-5 generations of all identified families to locate the earliest available birth places for family 
members to the confirm the geographic origin of the family. 
 
1.2 Family selection for the genome-wide scan and for haplotype association analysis 
 
In the genome-wide scan we included six pedigrees (Figure 1 of the original communication II). A 
total of 17 affected individuals were recognized, of which three were deceased at the time of the 
study. A total of 33 non-affected family members donated their blood samples for the genome scan 
analysis. For the haplotype association analysis the data set was extended by 12 nuclear families 
(proband, her or his spouse, and one offspring), two multiplex pedigrees without linkage 
information, and four singletons with a positive family history, but no DNA samples available from 
other family members. All nuclear families and singletons originated from the province of Savo and 
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the multiplex families from Central Southern Finland. A total of 33 patients and their 60 non-
affected family members were genotyped. In addition to family based controls (N=27), we 
genotyped two markers (2,902,739 and 2,921,606; equalling their physical position in contig 
NT_106606.15) in 23 unrelated individuals from the Savo region (Koskenmies et al. 2001), and in 
93 healthy blood donors from across Finland to estimate the frequency of the 2266-susceptibility 
haplotype in Finland. 
 
1.3 Replication data set   
 
During the study we continued to collect a replication data set (familial cases across the country, in 
collaboration with Finnish pulmologists and all cases in the Helsinki University district when first 
degree family members were available for genotyping). To date, the replication data set consists of 
one sib pair originating from the central part of Finland, and 10 sporadic cases from the Helsinki 
University district area. We have evaluated the susceptibility haplotype by genotyping the 2,902,739 
and 2,921,606 markers for these samples (similarily as described in paragraph 1.2).  
 
1.4 Patients and controls for association studies on the CR1 and ESCOD genes 
 
For the association study on CR1 (study III) the population consisted of 96 patients. The control 
population consisted of 96 voluntary blood donors across Finland and 68 healthy controls from the 
Savo region.  
 
Table 1. Clinical characteristics of the patients genotyped for the Arg213Gly variant in the ECSOD gene, the 
Pro1827Arg variant in the CR1 gene, and included in the fine mapping study. VC = vital capacity, DLCO = 
diffusing capacity for carbon monoxide. 
 
 
Characteristics of the patients 
          ECSOD                CR1     Fine mapping
Age, average (years);      (range) 62 (26-81) 62 (26-83) 62 (26-81)
VC (% of predicted);        (range) 71 (35-96) 74 (35-102) 69 (30-102)
DLCO (% of predicted);   (range) 57 (29-91) 58 (28-91) 57 (28-91)
Biopsy  (N) 11 17 % 17 18 % 6 18 %
Male/ Female  (N) 23/ 40 42/ 54 14/ 19
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For the association study on ECSOD (study IV) the patient population consisted of 63 patients (40 
females and 23 males). The control population consisted of 61 unrelated population based controls; 
28 of these were the spouses of the IPF patients. 
 
2. Diagnostic criteria 
 
The IPF diagnoses were made in accordance with the ATS/ERS international consensus statement 
(ATS 2000). The diagnostic criteria are shown in Table 2. For non-affected family-members, an 
interview revealed no clinical IPF in their medical history.  
 
Table 2. The diagnostic criteria for IPF. When a biopsy was unavailable, all the major criteria and at least 3 
of 4 minor criteria had to be fulfilled. For patients with a surgical biopsy showing UIP, only the major criteria 
were considered to be relevant.  
 
 Major Criteria  Minor Criteria 
1) Exclusion of other known causes of interstitial 
lung disease 
1) Age >50 years 
2) Abnormal pulmonary function with restriction 
and/or decreased diffusing capacity 
2) Insidious onset of otherwise 
unexplained dyspnoe 
3) Bibasilar reticular abnormalities on HRCT scans 3) Duration of illness >3 months 
4) BAL or TBB not pointing to another disease 4) Bibasilar, inspiratory crackles on 
auscultation 
 
All patients and controls signed a consent form when they donated their blood sample to the study. 
The Ethics committee of the Department of Medicine in Helsinki University Hospital, and the 
Ministry of Social Affairs and Health of Finland have approved the study. 
 
3. Genome scan and fine mapping markers and genotyping methods 
 
DNA was extracted from peripheral blood leukocytes by a standard non-enzymatic method (Lahiri 
et al. 1991). For the genome-wide scan, we used the Applied Biosystems Linkage Mapping Set 
MD-10 of 337 microsatellite markers. Genomic DNA (20 ng) was dried on microtiter plates for 
each PCR assay. The PCRs were performed in 5 μl volumes using reagent concentrations and 
temperature profiles as recommended by the reagent manufacturer (Applied Biosystems). The 
average interval between the markers was 10.6 cM. The genotyping success rate was 83%. The 
fluorescently-labeled PCR products were pooled (10-20 markers in each pool) and electrophoresed 
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in a Megabase 1000 capillary electrophoresis instrument (Molecular Dynamics). The alleles were 
called using the Genetic Profiler 1.1 software (Molecular Dynamics). 
 
Fine mapping of chromosomes 3, 4, 9, 12, and 13 was performed using a total of 63 additional 
microsatellite markers and one SNP. The order of the primers and their sequences used in 
genotyping are shown in Table E1 in the original communication (II). Fine mapping markers were 
genotyped either using capillary electrophoresis as described above or gel electrophoresis on an 
ABI377 sequencer. Alleles were called using Genotyper 2.0 (Applied Biosystems). PCR 
amplifications with fluorescently-labeled primers were done in 10 μl reaction volumes containing 
20 ng of genomic DNA, 0.5 μM of each primer, 0.2 μM of each dNTPs and 0.05 μM DNA 
polymeraze enzyme (AmpliTaqGold, Applied Biosystems) in the buffer with 2.5 mM MgCl2. The 
samples were denatured at 94°C for 10 minutes, and then subjected to 30 seconds at 94°C, 30 
seconds at 57°C and 30 seconds at 72°C for 35 cycles and were elongated for 10 minutes at 72°C. 
One SNP was genotyped from the short coiled-coil protein (SCOC) intron 1 (2739448A>G). 
Amplified PCR fragments were digested with the restriction enzyme EcoRI (New England 
BioLabs). The lengths of the PCR products were 175 and 117 basepairs (bp) for the minor alleles 
(A) and 292 bp for the major alleles (G). The reaction products were electrophoresed through 3% 
agarose gels stained with ethidium bromide for 2.5 hours and photographed under UV-illumination. 
Errors in Mendelian inheritance for all markers were checked using the PEDcheck program 
(O'Connell and Weeks 1998). 
 
4. Genotyping of the Pro1827Arg variant in the CR1 gene 
 
Genomic DNA comprising the Pro1827Arg polymorphism in CR1 was amplified using two primer 
pairs: 1) 5`CTTTTGTCCAAATCCTCCAG and 3`AAAGTTAAGCTCACAAACAAATACCA; 
and 2) 5`TTCAACCTCATTGGGGAGAG and 3`GGCAGGGCTGCTCCAAA. The PCR 
conditions were as follows: amplifications were performed in 10 ul reaction volumes containing 20 
ng genomic DNA, 0.25 mM of each primer, 0.2 mM of each dNTP, and 0.25 U thermostable DNA 
polymerase (AmpliTaqGold; Applied Biosystems) in the buffer recommended by the manufacturer 
with 2.5 to 3.5 mM MgCl2. The samples were denatured for 10 minutes at 94˚C, subjected to 31 to 
35 cycles each of 30 seconds at 94˚C, 30 seconds at 59˚C, 30 seconds at 72˚C, and elongated for 10 
minutes at 72˚C. The polymorphism was studied using two restriction enzymes HpyCH4III (PCR 
amplicon 1) and MnlI (PCR amplicon 2) (New England BioLabs). Different PCR amplicons were 
used to confirm unambiguous allele calling. The restricted PCR fragments were electrophoresed 
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through 2% agarose and 5% high resolution agarose gel (MetaPhor), respectively. PCR fragments 
were stained with ethidium bromide and photographed under UV-illumination. The length of the 
PCR product 1 for the major allele (C, referring to Pro1827) was 328 bp, and for the minor allele 
(G, referring to Arg1827) 164 bp + 164 bp (HpyCH4III specific restriction site). The lengths of  
PCR product 2 for the major allele (Pro1827) were 37 + 29 + 9 bp, and in the presence of the minor 
allele (Arg1827) 66 + 9 bp (MnlI specific restriction site). 
 
5. Genotyping of the Arg213Gly variant in the ECSOD gene 
 
The Arg213Gly variant in ECSOD was amplified using the primers 
5´CGCCAGGCGCGGGAACACTCAG3´ and 5´GGCGGACTTGCACTCGCTCTCG3´. One 
mismatch was induced in both primers: one to delete the second digestion site for MwoI and the 
other to reduce the formation of secondary structures by the primer pair. PCR amplifications were 
done in 10 µl reaction volumes containing 100 ng of genomic DNA with AmpliTaqGold 
Polymerase. After amplification, the PCR fragments were digested with MwoI (New England 
BioLabs) in the buffer recommended by the manufacturer. The lengths of the PCR products were 63 
bp for the minor allele (the Gly213 allele) and 28 bp and 35 bp for the major alleles (the Arg213 
allele). The reaction products were electrophoresed through 4 % agarose gels stained by Gelstar 
(FMC Bioproducts) and photographed under UV-illumination. 
 
6. Sequencing 
 
A critical 110 kB region identified in the genome-scan and exons 4 to 9 of the ELMOD2 gene were 
sequenced in order to identify all the sequence polymorphisms. The reference sequence was 
generated by assembling the sequence from the Human Genome Project (in contig NT_016606.15 
from position 2866166 to 2975765, a total of 109599 bp). Repeat regions such as SINE, LINE, 
LTR, MER1, and MER2 elements covered 48% of the sequence. A total of 157 PCR amplicons 
were designed to be ~650 bp in length with ~100 bp overlap with adjacent assays. Repeat regions 
were re-sequenced when possible to design primers in a unique sequence within the range 
mentioned above. SNP discovery was carried out in two selected patients (an affected father and his 
daughter), both heterozygous carriers of the identified susceptibility haplotype.  
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To reveal mutations in coding regions of the ELMOD2 gene, one patient representing each genome 
scan family and the haplotype-carrying father and his daughter were sequenced for all nine exons, 
and exon-intron boundaries of the ELMOD2 gene.  
 
PCRs were performed in 10 μl reactions containing 5 ng DNA, 3 mM MgCl2, 0.8 μM of each 
primer, 0.2 mM of each dNTP, and 0.03 U/μl of Hot Star TaqTM polymerase (Qiagen). Reactions 
were heated at 95 oC for 15 minutes, subjected to 40 cycles of amplification (30 seconds at 95oC, 30 
seconds at 50-62oC, and 30 seconds at 72oC) and a final extension of 10 minutes at 72oC. 
Unincorporated primers and dNTPs were removed by incubation with 0.4 U/μl of Exonuclease I 
(New England BioLabs) and 0.072 U/μl shrimp alkaline phosphatase (Amersham Biosciences) for 
30 minutes at 37oC. All exons were sequenced on both strands using the DYEnamic ET Dye 
terminator kit (Amersham Biosciences), following the manufacturer’s instructions. Cleaned 
sequencing products were injected for 80 seconds at 3 kW and electrophoresed for 100 minutes at 9 
kW or 180 minutes at 6 kW using MegaBACE long read matrix on a MegaBACE 1000 instrument 
(Amersham Biosciences). The sequences were analysed with the Sequence Analyser v3.0 software 
(Amersham Biosciences).  
 
To detect sequence variations, the sequence chromatograms were inspected visually by two 
independent readers and the sequences aligned using the Pregap and Gap4 softwares from the 
Staden package (http://staden.sourceforge.net). 
 
Genomic DNA comprising the Pro1827Arg polymorphism (PCR done with amplicon pair 1) was 
sequenced in an ABI3730 Automatic DNA sequencer (Applied Biosystems) (original 
communication III). 
 
7. mRNA expression 
 
Human Multiple Tissue cDNA panels I & II (BD Biosciences) were used for ELMOD2 and 
LOC152586 mRNA expression studies. ELMOD2 expression was studied also with the commercial 
Human Blood Fractions MTC cDNA panel (BD Biosciences), commercial fibroblast cell lines 
CCL-151 (healthy) and CCL-134 (derived from IPF patient), and lung biopsies. IPF biopsies were 
derived during transplantation operations from surgically verified UIP patients (N=6), and controls 
consisted of healthy lung areas derived from patients who went through thoracotomy because of 
solitary lung infiltrates (N=7). A pulmonary pathologist verified that the controls represented 
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healthy lung areas, and the diagnoses of all patients were based on light microscopic evaluations 
using the histologic criteria presented by Katzenstein and Myers (1998). The biopsies were 
retrieved from the Departments of Pathology and Pulmonary Medicine, Helsinki University Central 
Hospital.  
 
Total RNA was extracted from snap-frozen lung biopsies by mechanical homogenization and Phase 
Lock Gel Heavy kit according to the manufacturer´s (Eppendorf) instructions. cDNA was 
synthesized with TaqMan reverse transcription reagents (Applied Biosystems) and oligo dT primers 
according to the manufacturer´s instructions. PCRs were performed in 25 µl volumes containing 1.0 
µl cDNA as template, 2.5 µl 10X PCR Gold buffer, 1.5 mM MgCl2, 0.2 mM dNTPs (Finnzymes), 
200 nM primer, and 0.25 U AmpliTaqGold (Applied Biosystems) under the following conditions: 
94°C for 10 minutes; 36 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minutes 
followed by a final extension of 72°C for 10 minutes. The primer sequences for ELMOD2 were 5’-
TTCTTTGTGGGAGTTCTTCTA-3’ (spanning exons 2-9) and 5’-
TGAAAAGATTAAAGGACTTTTACTGGA-3’, respectively, and for LOC152586 5’-
CCGTCCCTGGCATTATCC-3’ and 5’-CTCAGTCGCTGCAATTTCC-3’ (covering 1143 bp of 
the cDNA), respectively. The accuracy of the PCR fragments was verified by sequencing. Primers 
for GAPDH were supplied with the kit and used according to the manufacturer´s instructions.  
 
The relative mRNA expression of ELMOD2 in the patient group was compared with controls after 
equalizing with the relative expression of mRNA GAPDH used as an endogenous reference gene. 
Syngene GeneTools software (Synoptics Ltd.) was used for detecting differences between intensities 
of the corresponding lanes.  
 
8. In vitro translation 
 
Capped RNA molecules of the LOC152586 gene were transcribed from an IMAGEclone 5267198 
DNA construct with T7 RNA polymerase (mMESSAGE mMASCHINE system, Ambion). 
Translation was performed with rabbit reticulocyte lysate translation machinery (Riboprobe in vitro 
translation system, Promega) in the presence of Redivue-L-[S35]-methionine (Amersham 
Biosciences) in the reaction mixture. The Xenopus elongation factor α (pTRI-Xef) DNA template 
was used as a positive control for transcription and translation, while in negative control, water 
replaced DNA. The translated polypeptides were detected by autoradiography after Tris-Tricine 
SDS-PAGE. 
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9. In situ hybridization 
 
The cDNA sequence of ELMOD2 was amplified from the IMAGEclone 3897166 with a primer pair 
containing the promoter sequence for SP6 and T7 RNA polymerase: forward (sense T7) 5’-
TAATACGACTCACTATAGGGTTCCGTCGTTTCCGTT-3’ and reverse (antisense SP6) 5’-
ATTTAGGTGACACTATAGAATTACAATCCAGTAAAAGTCCTTT-3’. Antisense and sense 
probes for ELMOD2 were transcribed by SP6 and T7 RNA polymerases (MAXIscript in vitro 
transcription kit, Ambion) in the presence of digoxigenin-11-uridine-5´-triphosphate (Dig-11-UTP, 
Roche).  
 
Non-radioactive in situ hybridization on tissue sections was performed with a Ventana DiscoveryTM 
device. In brief, the samples were deparaffinized with heat treatment followed by post-fixation and 
RiboClear pre-treatment. The samples were protease-treated for 18 minutes and hybridized for 6 
hours at 65°C with both antisense and sense probes. The slides were then washed three times with 
0.1X SSC (15 mM NaCl, 150 nM Sodium citrate, pH 7.0) at 75°C followed by the detection step, 
which included 20 minutes incubation with biotinylated anti-DIG antibody (Jackson 
ImmunoResearch Laboratories) and 2 hours incubation with the BCIP/NBT substrate. After the 
labelling, the slides were washed, dehydrated, and mounted with Mountex (HistoLab). All the 
reagents for DiscoveryTM were provided by Ventana Medical Systems except for protease K 
(Roche), which was used at a concentration of 350 ng/μl. 
 
10. Statistical analyses 
 
10.1 Linkage  analysis 
 
Genome-wide nonparametric multipoint linkage analysis and haplotype re-construction were done 
with GENEHUNTER 2.0 for six multiplex families (Kruglyak 1996). 
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To estimate the genome-wide power to detect linkage in our data set, we performed power 
simulations using the following model of inheritance: autosomal dominant with reduced penetrance 
of 0.9 and a frequency of the susceptibility allele in the population of 0.005. For linkage we used a 
two-point analysis with the 10 cM marker map. All markers had four equally informative alleles 
and no missing data was allowed. Iterations were made using the true pedigree structures, and the 
number of iterations was 2000. 
 
10.3 Association analyses 
 
Two-tailed Student’s tests were used to compare the differences between familial and sporadic IPF 
patients in the age of onset of the disease (study I), and to compare mRNA expression between 
cases and controls (study II). Comparisons between the patient and control groups were done using 
the chi square test (studies III and IV), and comparisons of susceptibility haplotype carriership 
between affected individuals and controls were analysed using Fisher’s two-sided exact tests. Odds 
ratios were calculated using the interphase at http://home.clara.net/sisa/fisher.html (study II).  
 
 
 
 
 
 
10.2 Power estimations for linkage analysis (simulations) 
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RESULTS 
 
 
1. Prevalence 
 
From the hospital data bases we were able to identify a total of 1445 in- or out-patients who were 
given the diagnosis J84.1 (Alveolitis fibroticans idiopathica) during the years 1997-1998 in Finnish 
pulmonary clinics. To verify the diagnoses we evaluated 50% of the medical records from eight 
centers; all five university hospitals, the two largest central hospitals and the largest regional 
hospital. These eight centers offered medical care for 66% of all identified patients. In each of these 
hospitals we used the proportion of confirmed diagnoses to extrapolate the total number of IPF 
patients per center. The percentages of confirmed diagnoses in different centres varied between 
49% and 77%. This range of variation was then used in the extrapolation of the number of IPF 
patients in the rest of the centres. Using this approach we were able to identify a total of 833-943 
IPF patients, equivalent to a prevalence of 16-18/100 000 among the Finnish population of 5.17 
million. Gender predominance was not perceived among the patients. 
 
IPF was more frequent in eastern Finland. In an area covering two hospital districts, the southern 
and eastern Savo Hospital districts, the prevalence was 45/100 000, which was more than twice 
the average (Figure 4). To identify the right patients, the medical histories in these centers were 
first reviewed by the local pulmologists and later a specialist from our group (U.H.) also went 
them through to see that there were no false positives to affect the high prevalence.  
 
The international guidelines (ATS/ERS 2000) encourage taking a lung biopsy to verify the 
diagnosis. According to the evaluated medical records, in 28.2% of cases (N =75) the IPF diagnosis 
was verified with a biopsy featuring a UIP pattern and the major criteria. In the remaining 71.8% of 
cases the diagnosis was based on the major and minor criteria, without biopsy verification.   
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2. Familial IPF 
 
Eighty-eight of the patients identified in the primary screen reported to us that they have or have 
had an affected family member. Medical records were then studied in detail. In 17 families we were 
able to verify 2 to 5 affected first-degree family members. The clinical course of the disease, HRCT 
scan findings, and histological appearance were indistinguishable between the familial and sporadic 
IPF patients. The age of onset, however, was slightly younger among the familial cases compared to 
that among the sporadic cases (mean 61.9 yrs vs. 65.3 yrs, p=0.11).  Again, no gender 
predominance was perceived. Based on this study approach, the prevalence of familial IPF was 5.9 
per million (31 living patients at the time of the study), explaining 3.3-3.7% of all the IPF cases. 
 
To study the geographic distribution of the multiplex families, we plotted the birthplaces of the 
parents of the probands on to a map of Finland (Figure 4). The majority of the parents originated 
from the same region where we also observed the highest prevalence of IPF. In this enrichment area 
we observed 50-fold risk of FPF compared to the rest of the country. The birthplaces of the parents 
clustered in certain neighbouring municipalities. The most significant clustering of 10 parents was 
found in 3 rural municipalities (Tuusniemi, Heinävesi and Kerimäki) in the province of Savo. The 
second cluster of five parents originated from three rural municipalities (Impilahti, Sortavala and 
Ruskeala) in Carelia, a province that formerly belonged to Finland. These two clusters are situated 
within 200 kilometers of each other. The Finnish origin of the families from Carelia was confirmed 
by their family names and their membership in the Lutheran church. By using parish records, we 
have been able to trace each family back 3-5 generations and found that these families were already 
settled in these regions generations ago, but no obvious loops between the pedigrees were observed. 
 
 
 
Figure 4. Birthplaces of the parents of the multiplex families in 
the genome-wide scan (♦). The southern and eastern Savo 
Hospital districts, where the prevalence was more than twice the 
average, are shown in gray. 
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3. Genome wide linkage analysis 
 
Genotyping was performed in six multiplex families, where 14 living patients and their 33 first-
degree relatives provided linkage information (GS in Figure 5). All of the formerly identified 17 
multiplex families were not suitable for the linkage analysis because 11 of these families did not 
provide information for linkage analysis. Five of the six pedigrees (Pedigrees 3, 4, 5, 13, and 17 in 
Figure 5) originated from the enrichment area in Savo  (Figure 4). The sixth pedigree (Pedigree 9 in 
Figure 5) originated 150 km west of the other families. 
  
For the genome-wide scan we used a commercially available microsatellite marker set (Applied 
Biosystems Linkage Mapping Set MD-10). The success rate of genotypes was 83%. The average 
interval between the markers was 10.6 cM. None of the markers showed an exceptional tendency 
for Mendelian errors. In the linkage analysis, the three best loci were located on chromosome 3, 
marker D3S1278 (NPL-score 1.7, p=0.06, information content 57%), on chromosome 4, marker 
D4S424 (NPL 1.7, p=0.05, information 60%), and on chromosome 13, marker D13S265 (NPL 1.6, 
p=0.06, information 71%). Using nonparametric linkage analysis (Kruglyak et al. 1996) none of the 
loci reached genome-wide significance. 
 
To better understand the power of our data set to detect true linkage in a genome-wide scan, we 
performed simulations. In the simulations we used the true pedigree structures and made the 
assumption that FPF is inherited in an autosomal dominant fashion with reduced penetrance. In the 
case of true linkage, the locus was identified in 60% of the permutations with a LOD score >1, in 
22% of the permutations with a LOD score >2, and 4% of the permutations with a LOD score >3. In 
the case of no linkage, LOD scores >1 at any given locus were observed only in 1.6% of the 
simulations. The results suggested that because of the small number of pedigrees, we could still 
miss true linkage with a likelihood that should be considered. Therefore, we visually inspected the 
haplotypes reconstructed by GENEHUNTER in all the chromosomal regions that showed positive 
NPL-scores and were potentially shared by the affected individuals within a family and across the 
families. Two chromosomal regions appeared to be of interest. On chromosome 9, all three patients 
in one family shared a 33 cM haplotype (markers D9S175, D9S167, D9S283, D9S287), while in 
five other families, 10 of 16 patients shared an allele as part of the haplotype either at D9S175 or 
D9S167. The best NPL-score of 1.3 was obtained for D9S167 (p=0.09, information 68%). On 
chromosome 12, a 25 cM haplotype (D12S364, D12S310, D12S1617, D12S345) was shared by six 
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of 16 patients and all 16 patients shared the same allele at least at marker D12S310 (NPL 0.48, 
p=0.3, information 56%). These five loci on chromosomes 3, 4, 9, 12, and 13 were all selected for 
fine mapping. The genome-wide scan results are shown in the original communication (II, Figure 
2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Pedigree structures in the genome-wide scan for familial IPF (GS), fine mapping (GS+ FM), and 
the susceptibility haplotype association study (GS+ FM+ HA). Affected family members are shown in black. 
Individuals who donated blood for genotyping are marked with an asterisk. The pedigree identification 
numbers are also used in Table 1, and Figures 1 and 3, of the original communication (II). 
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4. Haplotype association analysis on chromosomes 3, 4, 9, 12, and 13 
To maximize the information content for linkage and to detect or exclude a potential haplotype 
association, we used the principals of hierarchical genotyping in the extended family data set (GS + 
FM in Figure 5). The probands of the 12 nuclear families originating from the province of Savo, as 
well as the four singletons who had a positive family history, were also genotyped with fine 
mapping markers. We added a total of nine markers to 3q13, 28 markers to 4q31, six markers to 
9q21, four markers to 12p12-q12, and 17 markers to 13q31. With the additional markers linkage 
became stronger on chromosomes 3 (at D3S1303, NPL 2.07, p=0.05, information 83%), 
chromosome 4 (at D4S1586, NPL 2.09, p=0.02, information 74%), and chromosome 13 (at 
D13S281, NPL 2.4, p=0.01, information 84%), but weaker on chromosome 12 (at D12S310, NPL 
0.1, p=0.4, information 67%), and chromosome 9 (at D9S167, NPL 1.0, p=0.2, information 79%). 
In additional to weakened linkage results on chromosomes 9 and 12, potentially shared haplotypes 
were broken down (marker densities within the linkage peak after fine mapping were on average 4.1 
cM and 3.7 cM, respectively) and the chromosomes were excluded. On chromosome 3 with 
additional 9 markers (marker density on average 4.4 cM), no evidence of a shared haplotype 
between patients was found and it was excluded. On chromosome 13, a conserved haplotype among 
patients was observed, but the same haplotype was as common among the non-affected family 
members, showing no evidence of a disease association. 
 
Contrary to other loci, on chromosome 4 the patients shared a haplotype in eight of the 24 families 
(Figure 3, original communication II). The shared haplotype was at the shortest 110 kb and at the 
longest 13 cM, defined by 4-16 consecutive highly informative markers. At the shortest, the 
families shared four consecutive alleles 2266. The susceptibility 2266-haplotype was delimited 
upstream and downstream by two recombinations. 
 
In the Finnish population the frequency of the shared 2266-haplotype (2873878*2, 2894859*2, 
2902739*6, and 2921606*6) is rather low. Among the unrelated family-based controls, nobody 
(N=27 tested) was a carrier. To get a better estimate of the 2266-haplotype frequency, we 
genotyped markers 2902739 and 2921606. These markers were always inherited in LD and 
informative enough to tag the 2266-haplotype. The estimation was performed in a study group 
which consisted of 1) the patients (one family was represented by one affected family member) and 
their available spouses who were already genotyped in the genome scan and fine mapping studies 
(N=24 patients, N=27 controls) (GS+FM in Figure 5), 2) the replication data set with 10 patients 
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and one sibpair (N=11 patients) (HA in Figure 5), and 3) additional regional controls (N=23) and 
unrelated Finnish individuals (N=93). The total number of genotyped families was 35; 13 of these 
were multiplex families and 22 seemingly uniplex families. The total number of controls was 143; 
50 regional and 93 across Finland.  None of the patients or controls was a homozygous carrier of 
the haplotype. In 38% (5/13) multiplex families, the affected family members shared the 
susceptibility haplotype (families 6, 17, 18, 34, 36 in Figure 5). Correspondingly, in 27% (7/22) 
uniplex families (families 21, 23, 24, 31, 73, 74, and 77 in Figure 5) the proband was a 2266-
haplotype carrier. Among the control individuals from the Province of Savo, the heterozygous 
carriership of the haplotype was 4% (2/50), and 9.6% (9/93) among the controls across Finland, 
respectively. The carriership of the susceptibility haplotype was significantly higher among the 
patients (12/35) when compared to the regional controls (2/50 individuals, OR=12.5, 95%CI=2.6–
60.6, p=0.0004), and to the combined pool of controls (11/143 individuals, OR=6.3, 95%CI=2.5-
15.9, p=0.0001).  
 
5. Positional candidate genes 
 
Based on the human gene annotations publicly available, at least two genes are located within the 
susceptibility haplotype (http://www.sanger.ac.uk, http://www.genome.ucsc.edu, Stausberg et al. 
2002). One of the genes is ELMOD2 (also known as MGC10084, HGNC:28111, 9830169G11Rik) 
(GenBank Source: BC015168, GeneID: 255520), and the other is LOC152586 (GeneID: 152586, 
similar to RIKEN cDNA 4933434I20). The genes are encoded in opposite directions, but are not 
overlapping. Three exons, 1-3, of the ELMOD2 gene are located within the 110 kb critical region, 
whereas the entire coding sequence of LOC152586 occurs totally within that region (Figure 4, 
original communication II).  
 
ELMOD2 consists of nine exons encoding a 293 amino acid protein. The experiments with the 
commercially available human tissue cDNA panels showed that this gene is expressed in multiple 
tissues and cell types, including the lung, and both in healthy and IPF-derived fibroblasts (Figure 5, 
original communication II). mRNA expression of ELMOD2 was further studied with lung biopsies 
derived from patients with verified UIP (N=6). The biopsies were taken during lung transplantation, 
which was performed because of end-stage IPF. The control biopsies were from healthy lung areas, 
confirmed by a pulmonary pathologist, from patients who underwent oparations because of solitary 
lung nodules (N=7). The mean intensity of mRNA expression was significantly decreased among 
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the patients compared to the controls (p=0.05) (Figure 7, original communication II). Using in situ 
hybridization we detected the expression of ELMOD2 in epithelial cells and alveolar macrophages 
of a healthy adult lung (Figure 6, original communication II). The function of ELMOD2 is poorly 
known, but it belongs to a protein family that expresses a highly conserved domain found in a 
number of eukaryotic proteins including CED-12 and ELMO1-3. These molecules are known to 
interact in signaling pathways involved with apoptosis, phagocytosis, cell engulfment, and cell 
migration. 
 
LOC152586 is even less well characterized. Several overlapping expressed sequence tags (ESTs) 
that are most probably encoded by a single gene can be found in the Human Genome Assembly 
Data Base. Extensive altered splicing is suggested from different transcripts and all potential open 
reading frames are short. All the identified exons are located within the critical region. Based on 
RT-PCR results this gene was only expressed in the testis (Figure 5, original communication II). 
We carried out an in vitro translation assay using an IMAGEclone 5267198 that contained one of 
the longest potential open reading frames (147 amino acid), and we failed to produce any peptide 
(Figure 5, original communication II).   
 
6. Sequencing 
 
In order to identify possible genetic variation in the susceptibility haplotype, we sequenced this 
region (from position 2,866,166 to 2,975,765 in the public sequence NT_016606.15) in two 
individuals (an affected father and his daughter), both heterozygous carriers of the haplotype. When 
the sequences were compared to the public sequence (NT_016606.15), we observed 39 
polymorphisms: 19 were heterozygous and 18 homozygous single nucleotide polymorphisms, one 
single nucleotide insertion, and one two-nucleotide deletion (Table E2, original communication II). 
Most of the polymorphisms had not been previously reported. None of them appeared to locate on 
the coding areas of either ELMOD2 or LOC152586.  
 
All nine exons of the ELMOD2 gene (including exons 4-9 outside of the critical region) were 
sequenced in the affected father and his daughter, and in six patients representing each genome scan 
family. No differences between the exons and the public sequence were detected. 
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7. Association study on the Pro1827Arg variant in the CR1 gene 
 
The Pro1827Arg polymorphism in CR1 was studied among 96 IPF patients and 164 controls. For 
genotyping we used two different restriction enzymes recognising different restriction sites to detect 
the studied polymorphism. HpyCH4III did not digest any of the PCR fragments, suggesting that all 
patients and controls were Pro1827 homozygous. In the absence of positive controls, we confirmed 
the genotyping results with another restriction enzyme, MnlI. Consistent with the previous results, 
again, only the major allele (Pro1827) was recognized. Since the results did not match our primary 
hypothesis, we then verified by sequencing that all patients were Pro1827 homozygous, and that the 
site is not polymorphic among Finns. 
 
8. Association study on the Arg213Gly variant in the ESCOD gene  
 
The Arg213Gly polymorphism in ECSOD was studied in 63 IPF patients and 61 population-based 
control subjects. The carriership of the Gly213 allele was 2.5%. One of the patients and three 
control subjects were heterozygous carriers of the Gly213 allele. There was no association between 
the Gly213 allele and IPF. The study showed that the polymorphism is very rare among Finns and 
our study design had limited power to show an association or exclude it.   
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DISCUSSION 
 
 
1. Prevalence of IPF 
 
Since the first description on fibrosing alveolitis by Hamman and Rich in 1944 it has become 
obvious that patients with interstitial pneumonias show differences in the clinical presentation as 
well as in histological appearance. Gradually it was noticed that IPF differs from other IIPs not only 
in its clinical and histological manifestations, but also in the pathogenesis and prognosis. Because 
of the variable and confusing diagnostic criteria and terminology of IIPs, the international 
multidisciplinary panel, nominated by the American Thoracic Society and the European Respiratory 
Society, released international consensus statements concerning first, IPF: diagnosis and treatment 
(ATS 2000), and second, classification of the IIPs (ATS 2002). 
 
Our study on the nationwide prevalence of IPF was the first retrospective survey done according to 
the novel criteria to diagnose IPF. Evaluation of the case records showed that the diagnosis J84.1 
according to the ICD-10 classification, which should refer to IPF, was used quite liberally as a 
primary diagnosis for diffuse paranchymal lung diseases. In clinical practice, the diagnosis J84.1 
was obviously used as a primary diagnosis and then specified later in the diagnostic process when 
other causes for symptoms and lung involvements were determined. Depending on the center, 23% 
to 51% of the patients were excluded. The excluded patients suffered from a variety of interstitial 
lung diseases, such as connective tissue disease-related pulmonary manifestations, cryptogenic 
organizing pneumonia, eosinophilic pneumonia, asbestosis, radiation therapy-related or 
nitrofurantoin-induced fibrosis, allergic alveolitis, and eosinophilic pneumonia.  
 
The prevalence of IPF in Finland was 16-18/100 000, which is in concordance with reports from 
other populations (Scott et al. 1990, Coultas et al. 1994, Iwai et al. 1994, Hubbard et al. 1996). In 
study I, southern and eastern Savo showed a prevalence of 45/100 000, a more than two-fold 
increase compared to the nationwide prevalence. The diagnostic accuracy was confirmed by re-
evaluating the case records. The re-evaluation further confirmed the higher prevalence and the 
enriched geographical distribution. 
 
 
  58
2. Familial IPF 
 
Familial and sporadic forms of IPF are clinically and histologically indistinguishable, suggesting 
common pathogenic pathways (Marshall et al. 1997, Marshall et al. 2000, Lee et al. 2005). Our 
clinical findings in familial cases in study I revealed no other differences except a slightly younger 
age at the time of diagnosis among FPF patients (61.9 yrs vs. 65.3 yrs, p=0.11). Additionally, we 
observed no differences in the clinical characteristics between the familial patients studied in the 
genome-scan, fine mapping and haplotype association analyses and the sporadic patients in the 
haplotype association study (Table 1, original communication II). Therefore, we can assume that by 
discovering genetic defects in familial IPF, the results can pinpoint genes and signaling pathways of 
interest also for the sporadic forms of the disease. 
  
During our study we were able to identify 17 families with 2-5 affected family members. Most of 
the affecteds were siblings, only three parent-offspring pairs were detected (Table 2, original 
communication I). The low number of parent-offspring pairs may be due to several reasons. Some 
of the parents had died before the age of 60 from other causes. In some cases the probands most 
likely have insufficient knowledge of their family disease history, and the diagnostic procedures to 
identify the disease were limited among the older generations. We had excluded IPF among the 
non-affected family members through an interview by asking whether they were diagnosed with 
any IIP. It is known that especially first degree relatives may express some signs of the disease 
(Bitterman et al. 1996, Steele et al. 2005), and it is therefore possible that we have ruled out some 
appropriate families. The number of familial cases identified implied a prevalence of 5.9 per million 
for familial IPF, explaining 3.3–3.7% of IPF in Finland. That is four times higher than reported in 
Great Britain (Marshall et al. 2000). Preliminary reports from the United States suggest that the 
familial form may explain even 20% of IPF (Loyd 2003). 
 
The birthplaces of the parents of our IPF patients were plotted on to the map of Finland. 
Surprisingly, the majority were clustered in the southern and eastern Savo region; the very same 
region where we observed that the prevalence of IPF was two times higher than in the rest of 
Finland. Each family has been traced back 3-5 generations and according to parish records these 
families were settled in these same regions already in the beginning of the 19th century. We were 
not, however, able to detect any direct genealogical loops between the families. Clustering of IPF 
families has been partially explained by common environmental factors (Steele et al. 2005). In none 
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of the familial cases was exposure to any known environmental risk factors for IPF. Therefore, the 
strong clustering supports the importance of genetic factors in the pathogenesis of IPF. 
 
Among the Finns, for many inherited diseases, one major mutation is present in > 70% of disease 
chromosomes (Peltonen et al. 1999). Although some of the diseases are spread throughout the 
country, they are mainly caused by the same mutation event carried to Finland. When a disease is 
caused by one major mutation, LD is likely to be detected. The longer the observed genetic interval 
showing LD, the more obvious the clustering of the grandparents of patients and the younger the 
disease-predisposing mutation (Peltonen et al. 1999). Within Finland the longest observed LD 
intervals are 13 cM for congenital chloride diarrhea (Höglund et al. 1995), in which the families 
originated from the subpopulation of Kainuu, and 11 cM for vLINCL, in which the origin of 
families is in southern Botnia (Varilo et al. 1996). The pattern of the distribution of the grandparents 
of patients with vLINCL (Varilo et al. 1996) remarkably resembles that of the parents of FPF 
patients. Combining the geographical distribution of the parents of the FPF patients and the 
knowledge of Finnish population history, we assumed that patients with FPF might share a 
common, ancestral disease-causing allele, and due to the founder effect, with a even smaller study 
population this might be possible to identify. 
 
3. Identifying novel candidate genomic region for IPF by genome-wide scan combined with 
hierarchial association study 
 
Collecting families with ≥ 2 affected family members suitable for studying linkage in IPF is 
challenging; IPF is a quite rare disease with late onset and short survival after diagnosis, and the 
phenotypes also have to be accurate. In our nationwide study we identified 17 multiplex families. 
All the families were willing to participate in the study. In six of the families there were sufficient 
family members delivering linkage information, and they were included in the genome-wide scan 
without further selection. In three of the originally identified families, all the affected family 
members had died before we were able to contact them. In six families there was one living patient 
and in two families an affected parent-offspring pair who participated along in the study with their 
first degree family members. Five of the six genome scan families originated from the above 
mentioned Savo cluster (Heinävesi-Tuusniemi-Kerimäki). Based on power estimations assuming 
that at least some of the probands are offspring of the same ancestor, we presumed that most likely 
these six families would not provide enough information to find a significant linkage signal (Lander 
and Kruglyak 1995). Therefore, already before the genome scan, we made simulations to estimate 
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the power of our data set to obtain significant linkage. According to the simulations, it was possible 
to miss true linkage, and therefore we included in the fine mapping also the regions that showed 
potential haplotype sharing. 
 
The genome-wide scan identified five interesting regions; on three chromosomes (3, 4, and 13) loci 
obtained NPL-scores of 1.6-1.7, and on chromosomes 9 and 12 a possible shared haplotype was 
detected. These regions were characterized in more detailed with fine mapping, which was 
performed with a hierarchial strategy. For fine mapping we recruited two other families with FPF 
without linkage information, 12 trios, and four singletons from the region of IPF enrichment. After 
fine mapping, the possible haplotypes seen on chromosomes 9 and 12 were broken and the NPL-
scores decreased, to 1.0 and 0.1, respectively, and these chromosomes were not studied further. On 
chromosomes 3 and 13 the NPL-scores increased, to 2.1 and 2.4, respectively. After the fine 
mapping the average distances between markers were 4.4 cM and 2.2 cM on chromosomes 3 and 
13, respectively. On chromosome 3 we were unable to see any shared haplotypes. On chromosome 
13, on the other hand, a shared 7 cM haplotype was obvious, but as it was seen as frequently among 
patients and non-affected family members, we considered it to merely represent a common 
haplotype.   
 
After adding 31 markers on chromosome 4q31.1 the marker D4S1586 obtained suggestive linkage 
with an NPL-score of 2.1 (p=0.02, information 74%). The flanking region included the 110 kb 
haplotype that was shared by one third of the patients, and was not detected among any of the non-
affected family members. Because our data set was small, we screened the susceptibility-haplotype 
in our replication data set in an affected sister pair and 10 single IPF patients. The sister pair and 
three singletons carried the susceptibility-haplotype consistent with our previous findings. The 
susceptibility haplotype was detected in 7.7% of regional (2/50) and non-regional (9/93) Finnish 
controls, significantly less frequent than among the IPF patients (34%), and resulting in an odds 
ratio of 6.3 (95%CI=2.5-15.9, p=0.0001). To rule out the possibility that the identified susceptibility 
haplotype is only a regional enrichment of a rare haplotype we compared the patients and regional 
controls, and the difference was still highly significant (OR 12.5, 95%CI=2.6-60.6, p=0.0004). If 
we have misinterpreted true IPF cases as unaffected we may have weaken, but not overestimated, 
the association.  
 
Although the frequency of the susceptibility haplotype was slightly higher among the multiplex 
families than among the uniplex families (38% vs 27%), carriership could not separate them 
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phenotypically. The carriership of the susceptibility haplotype did not seem to modify the clinical 
disease: the clinical characteristics of the haplotype carriers and non-carriers patients were 
indistinguishable. Five of the multiplex families and four of the uniplex families originated from the 
enrichment area. It is presumed that some of the seemingly uniplex families are multiplex families, 
but due to the lack of pedigree information, and renewed diagnostic methods, the familiality is not 
recognized. One of the multiplex and one of the uniplex families shared a common 8 Mb haplotype 
(families 17 and 21 in Figure 3, original communication II), which further suggests that they are 
related within 10-15 generations.   
  
In order to identify possible mutations the susceptibility haplotype-comprising region was 
sequenced in a father carrying the haplotype, and his daughter. When compared with the public 
sequence, the sequencing revealed 37 SNPs (Table E2, original communication II). None of the 
polymorphisms were located in the coding areas of the LOC152586 gene, or in exons 1-3 of the 
ELMOD2 gene, nor were they predected to alter reading frames or altered splicing sites. The 
identified susceptibility haplotype was a rather SNP- and gene-poor region of the genome. 48% of 
the region was excluded from the sequencing based on repetitive sequence. Whether the excluded 
region includes polymorphisms that may result in altered function of these genes is unknown and 
deserves to be clarified further. Thus far, when no functionally important mutations within the 
haplotype-comprising region have been identified, we cannot claim any correlation between the 
susceptibility haplotype and the risk of clinical manifestation of the disease.  
 
4. Characterization of candidate genes 
 
According to the recent public databases, two genes are located within the critical region 
(http://www.sanger.ac.uk, www.ncbi.nih.gov/IEB/Research/Acembly), ELMOD2 and LOC152586.  
The sequence of ELMOD2 is defined by 140 cDNA clones. The gene consists at its longest of nine 
exons and is alternatively spliced into 4 different transcripts, together encoding 4 different protein 
isoforms. The longest protein isoform is 293 amino acid long, with a molecular weight of 34.9 kDa. 
There are 3 probable alternative promoters and 2 non-overlapping alternative last exons. The gene 
covers 29 kb on the direct strand, and exons 1-3 are encoded within the critical region 
(www.ncbi.nih.gov/IEB/Research/Acembly). According to the public databases and our own 
mRNA expression studies, ELMOD2 is expressed at very high levels in various tissues and cell 
types, among them lung and fibroblasts, which are both relevant in the pathogenesis of IPF. Using 
in situ hybridization we recognized expression of ELMOD2 in alveolar macrophages and alveolar 
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walls in healthy adult lung. mRNA expression studies showed that the expression of ELMOD2 is 
decreased in IPF lung compared to healthy lung. That might reflect that the lack of ELMOD2 
expression is associated with IPF. Because we do not understand the function of ELMOD2, we 
cannot state whether the lack of expression leads to the fibrotic process, or if it`s just an end-stage 
phenomenon in mature fibrosis.  
 
ELMOD2 belongs to a family of protein with a highly conserved domain which is found in a 
number of eukaryotic proteins including CED-12 and ELMO1-3. It is similar to the Caenorhabditis 
elegans gene, ced-12, which is required for the engulfment of dying cells and cell migration. Its 
function is poorly understood, but due to the conserved motif it is thought that ELMOD2 plays a 
part in regulating phagocytosis, and participates in apoptosis and cell migration (MIM 606420-
606422, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM). All of those are functions that 
may play a role in the pathogenesis of IPF, and thus suggesting ELMOD2 not just a positional, but 
also a functionally promising candidate gene for IPF.  
 
The other gene, LOC152586, is coded in the reverse direction with the whole 0.5kb coding area 
within the critical region. The function has not been characterized, but overlapping ESTs most 
probably are encoded by a single gene, and have been recognized in broad spectrum of human 
tissues showing extensive splicing. EST sequences include open reading frames; the longest one, 
147 bp, we identified from the sequence supported by human cDNA IMAGEclone 5267198. 
According to our in vitro translation experiment LOC152586 may not be a protein-coding gene. 
The sequence, however, is defined by 3 cDNA clones, and appears to contain a domain that has 
homology to a mouse genome (ref:NP_036346.1 vs. ref:NP_080509.1). The conserved domain 
suggests that it may possess a regulative function on translational or transcriptional phases of 
protein production. 
 
Because the true disease-causing variant may occur only in a subset of patients with the 
susceptibility haplotype, we sequenced one patient from each of the genome scan families, and a 
haplotype-carrying father and his daughter for all nine exons and exon-intron boundaries of 
ELMOD2, but we found no mutations. Therefore, a mutation within the coding region does not 
explain the altered function or expression of ELMOD2 in our data set.  
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Intronic SNPs obviously do not change the structure of the encoded protein, but there is increasing 
evidence that not only coding, but also non-coding, sequences can have deleterious effects on 
splicing and change expression levels (Pagani et al. 2003, Pagani and Baralle 2004). This has been 
reported in several disease gene-mapping studies, even though the diseases-causing mechanisms 
remain poorly understood (Karlin et al. 2002, Laitinen et al. 2004, Pastinen and Hudson 2004). 
Expression levels are controlled both by cis-acting factors, such as DNA polymorphisms and 
methylation in the flanking DNA sequence, and trans-acting factors, such as transcription factors, 
that are in turn influenced by other genetic and environmental modulators (Pastinen and Hudson 
2004). Identifying the epigenetic mechanisms and factors that together with the genomic variant(s) 
change the phenotype will be challenging.  
 
5. Association studies on functional candidate genes CR1 and ECSOD 
 
The CR1 gene is an important part of innate immunity in lung (Cornakoff et al. 1983, Davies et al. 
1992). The polymorphism Pro1827Arg in exon 33 creates a potential cleavage site for trypsin-like 
proteases that can increase the shedding of receptors expressed on the cell surface (Herrera et al. 
1998).  An association with Pro1827Arg had been reported previously among Italian IPF patients 
(Zorzetto et al. 2003). According to our results the site was not polymorphic among the Finns. 
 
The CR1 protein is composed of repeated motifs of 65-70 amino acids, and almost identical repeats 
of sequences occur within the coding region of the CR1 gene. For example, the lengths of both 
exons 33 and 41 are 228 bp, and they differ from each other by only 7 nucleotides. However, the 
intronic regions between exons are unique, which makes it possible to design specific amplicons for 
different exons. Later, in our correspondence to Zorzetto et al. (2005), it became obvious that the 
polymorphic site they had reported was not in exon 33 but in exon 41 (Hodgson and Laitinen 2005).  
 
Based on unfortunately misleading information of the location of the SNP of interest, our study, in 
fact, did not confirm or exclude the association reported by Zorzetto et al. (2003). It became also 
evident that the corresponding C>G substitution in exon 33 is a monomorphic site based on our 
own and the Italian study (original communication II, Zorzetto et al. 2005). The polymorphism 
should preferably be called Pro2277Arg  rather than Pro1827Arg in the future. 
 
The ESCOD gene maps to chromosome 4 (4pter-q21) (Hendrickson et al. 1990). The ECSOD 
protein has high affinity for collagens and glycosaminoglycans, and this affinity is regulated by the 
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six amino acid motifs (Arg-Lys-Lys-Arg-Arg-Arg) within the last 14 amino acids (Sandström et al. 
1992, Sandström et al. 1994, Folz and Crapo 1994). A single nucleotide change from C to G that 
leads to an amino acid change from arginine to glycine, Arg213Gly, (Arg-Lys-Lys-Gly-Arg-Arg) 
has been reported (Folz and Crapo 1994). The polymorphism is associated with higher levels of 
serum ECSOD (Sandström et al. 1994), assumed to be due to the decreased affinity to ECM 
(Adachi et al. 1996). The increased activity of ECSOD in the ECM is known to protect from lung 
injury caused by free radicals (Oury et al. 1996).  
 
In our study the Gly213 allele was shown to be a rare variant in the population (2.5%), which is in 
acconcordance with observations among Swedish populations (2.2-3.8%) (Marklund et al. 1997). 
The relationship of this polymorphism with lung diseases has been studied among asthma patients, 
but no association was revealed (Kinnula et al. 2004). We found no association of the Arg213Gly 
polymorphism with IPF. Therefore, other factors regulating the role of ECSOD in IPF do matter.  
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Future challenges 
 
Understanding the molecular genetic mechanisms in the pathogenesis of IPF gives us the 
opportunity to reach for effective therapies for IPF patients. Because the phenotypes of familial and 
sporadic IPF cannot be distinguished, familial IPF can give us unique insight into the pathogenesis 
of IPF. IPF is a complex disease, and it is obvious that identifying one disease-predisposing gene 
would give us one new tool to discover parts of the etiology of IPF. Although IPF does not differ in 
its clinical presentation and outcome between different populations, it is crucial that the results we 
have obtained among Finnish IPF patients be verified in other, and especially larger, populations. 
Our genome scan among Finnish families pointed to two novel positional candidates. Based on 
functional and expressional properties, especially ELMOD2 is proposed as a prime candidate 
susceptibility gene for familial IPF. Characterization of the genes, and the function and expression 
of both ELMOD2 and LOC152586 is our next challenge on the way to better evaluate the possible 
role of these genes in the etiology and pathogenesis of IPF.  
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CONCLUSIONS 
 
We estimated the first nationwide prevalence of IPF according to the present diagnostic criteria. 
The prevalence of IPF in Finland was 16-18/100 000 inhabitants. A geographical clustering with a 
prevalence of 45/100 000 was observed in southern and eastern Savo.  
 
The familial form explains 3.3-3.7% of all IPF cases in Finland. The distribution of the origins of 
identified FPF patients clustered remarkably to southern and eastern Savo. Ten of the families 
originated from two clusters close to each other in Savo and Carelia. FPF patients may share a 
common ancestor who introduced the disease-predisposing allele into the population.  
 
The genome-wide scan combined with haplotype analysis with a dense marker map identified a 
110 kb region on chromosome 4q31.1. The locus obtained an NPL score of 2.1, exceeding the 
suggestive linkage threshold. The susceptibility haplotype was shared by one third of the patients.  
 
The susceptibility haplotype harbors two functionally poorly characterized genes, ELMOD2 and 
LOC152586. ELMOD2 is potentially involved in apoptosis, phagocytosis, cell engulfment, and 
cell migration. It is expressed in functionally relevant tissue, in lung and in fibroblasts, and its 
expression is significantly decreased in IPF lung compared to healthy lung. Therefore ELMOD2 
becomes a prime candidate gene for familial IPF. 
 
The Pro1827Arg of CR1 gene in exon 33 was formerly reported to be associated with IPF. The 
site in exon 33 appeared to be monomorphic. The polymorphism is located in exon 41, and should 
preferably be called Pro2277Arg. The functionally promising polymorphism Arg213Gly in 
ECSOD was not associated with IPF among Finnish IPF patients.  
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